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Parkinson’s disease (PD) is the second most common neurodegenerative disorder in old age. 
The presence of akinesia, rigidity and rest tremor caused by dopaminergic neuronal loss in the 
substantia nigra are the major clinical hallmarks of PD. Although several treatments can 
temporarily improve motor symptoms and the quality of life in PD patients, it is still incurable 
until now. PD is neuropathologically characterized by aggregation of misfolded α-synuclein 
in dopaminergic neurons, neurodegeneration and neuroinflammation. Translocator protein 18 
(TSPO) is a mitochondrial protein which is upregulated in microglia during 
neuroinflammation, and several TSPO ligands have been shown to exert neuroprotective 
effects in neurodegenerative diseases. In this study, we investigated the potential 
neuroprotective effects of Emapunil (also known as AC-5216 or XBD-173), a TSPO ligand, 
in female mice with subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
treatment, and in 1-methyl-4-phenylpyridinium (MPP
+
) treated human dopaminergic cell line 
Lund Human Mesencephalic (LUHMES). 
We find, that application of Emapunil protects against dopaminergic neuron loss, preserves 
dopamine metabolism, and also improves motor performance. Furthermore, Emapunil 
treatment ameliorates MPP
+
 and rotenone toxicity in LUHMES cells.  
We identified that Emapunil inhibits endoplasmic reticulum (ER) stress-induced activation of 
the IRE1α/XBP1 (X-box binding protein 1) pathway, which can result in apoptosis. In 
addition, Emapunil induces the shift from pro-inflammatory M1 to anti-inflammatory M2 
microglia activation state. Given that Emapunil has been found to be safe and well-tolerated 
in a phase II clinical trial, our results indicate that Emapunil could be a promising drug for PD 
patients.  




1.1 Parkinson disease (PD) 
1.1.1 Milestones of PD research  
PD was first scientifically described by James Parkinson in his monography “An Essay on the 
Shaking Palsy” in 1817 (Parkinson 2002). Several clinical symptoms which include tremor, 
rigidity and walking problems were described in this essay (Parkinson 1997). More than 50 
years later, Jean-Martin Charcot named this disease “Parkinson's disease” after separating it 
from other tremor disorders, such as Multiple Sclerosis (MS) (Charcot 1869). The first 
hypothesis on pathogenesis of PD was proposed by Édouard Brissaud in 1895, who 
speculated that its pathology starts from subthalamic regions or the cerebral peduncle 
(Brissaud 1895). Friedrich first described inclusion bodies in PD postmortem tissue, later 
named “Lewy bodies” (LBs) (Lewy and Handb 1912). 
In 1919, Konstantin Tretiakoff proposed that the mainly affected cerebral structure in PD 
patients was the substantia nigra (Trétiakoff 1919), which was further confirmed by Rolf 
Hassler in 1938 (Hassler 1938). Later, the Nobel Prize laureate Arvid Carlsson and colleagues 
elucidated the critical effect of the neurotransmitter dopamine in PD pathogenesis in the late 
1950s. L-DOPA as a therapy for PD was subsequently developed, which is still the most 
commonly prescribed drug for PD (CARLSSON and WALDECK 1958). 
In the 1990s, for the first time, a genetic background of PD was revealed as SNCA in 
autosomal-dominant familial PD, which codes for α-synuclein (Polymeropoulos et al. 1997). 
Several days later, α-synuclein was unveiled as the major component of Lewy bodies within 
brains of sporadic PD patients (Spillantini et al. 1997).  
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In the last two decades, unprecedented progress has been made in PD research: Different PD 
pathological stages were defined (Braak et al. 2003); more and more genetic risk factors have 
been identified by genetic linkage analysis and large genome-wide association studies 
(GWAS). Despite the progress in understanding its pathophysiology, PD is still incurable, and 
all clinical trials with disease-modifying therapies have failed so far. The standard treatment 
for PD is dopamine or dopamine agonists which is a symptomatic treatment that ameliorates 
the motor symptoms but does not interfere with the pathogenesis. 
1.1.2 Epidemiology  
PD is the most common movement disorder and the second-most common neurodegenerative 
disorder in the world, following AD (Twelves et al. 2003). Its prevalence dramatically 
increases with aging, and the onset of the disease is usually from 60 years old (Twelves et al. 
2003; Savica et al. 2013; Van Den Eeden et al. 2003). PD affects approximately 2-3% of the 
population aged 65 years or older (Pringsheim et al. 2014), and genetic factors are thought to 
be involved in 5-10% of all cases (Pinter et al. 2015).  
In most populations, men have an approximately 2 fold risk of PD than women (Van Den 
Eeden et al. 2003; Baldereschi et al. 2000). Female sex hormones might contribute to this 
male preponderance (Kusumi et al. 1996). The prevalence rates also vary within subgroups 
defined by ethnicity or environment (Van Den Eeden et al. 2003). 
Worldwide, the survival time after PD onset has been rising between 1990 and 2010, because 
of the improvement in health care. However, the mortality rate of PD patients is still double 
compared with the age-matched healthy population, starting from the second decade after PD 
onset (Lix et al. 2010). With the increased aging population worldwide, the estimated number 
of PD patients and the associated family, societal and economic burden will continuously 
increase (Dorsey et al. 2007; Vos et al. 2012; Murray et al. 2012; Leibson et al. 2006). 
  Introduction 
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1.1.3 Neuropathology  
The neuropathological hallmarks of PD include the loss of the dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) (Dickson et al. 2009; Halliday et al. 2011) and the 
presence of intraneuronal proteinaceous inclusions within neuronal axons or cell bodies, 
termed Lewy neurites or Lewy bodies (LBs), respectively.  
The selective loss of dopaminergic neurons and their axon terminals which are projected to 
the dorsal striatum leads to motor symptoms in PD patients, which includes rigidity, 
bradykinesia, postural instability and resting tremor (Goedert et al. 2013). These motor 
symptoms normally present when approximately 50% of dopaminergic neurons have been 
lost (Dijkstra et al. 2014; Iacono et al. 2015; Gibb and Lees 1991). The dopamine replacement 
therapy (DRT) can temporarily compensate the dopamine loss and is used as the standard 
treatment for ameliorating motor deficits. However, the long-term DRT can cause aberrant 
neuronal plasticity by itself, which further results in involuntary dyskinesia (Nishijima et al. 
2014; Schapira et al. 2009). Besides, PD patients commonly suffer from a huge range of non-
motor symptoms, including hyposmia, pain, somatosensory disturbances, sleep disorders, 
anxiety, depression, cognitive disorders and dementia, which are also caused by deficits of 
dopamine or other neurotransmitters in the central and peripheral nervous system (Schapira et 
al. 2017). Non-motor symptoms can occur before motor deficits and become dominant in 
advanced PD patients, which severely impairs the quality of life and shortens the life 
expectancy (Marinus et al. 2018). 
LB pathology is another neuropathological hallmark of PD. These intraneuronal 
proteinaceous inclusions are enriched in aggregated forms of the α-synuclein and associated 
with post-translational modifications, like phosphorylation and ubiquitination (Dickson 2012; 
Spillantini et al. 1997; Ciechanover 2005). By assessing the presence of LBs in a large cohort 
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of post-mortem tissue, Braak proposed a staging system of the spreading LB pathology to 
better characterize PD progression (Braak et al. 2003; Braak et al. 2004; Braak et al. 2006; 
Braak and Del Tredici 2008). Based on Braak’s scheme, the LB pathology is divided into six 
stages: 1-2 are the presymptomatic stages; 3–4 are the early symptomatic stages; and 5–6 are 
the late symptomatic stages. In stage 1, Lewy neurites and LBs initially start from lower 
brainstem and olfactory nerves, as well as the dorsal motor nucleus of the vagus nerve in 
medulla oblongata; in stage 2, Lewy neurites and LBs move up along the brainstem and are 
presented in medulla oblongata and pontine tegmentum, e.g., caudal raphe nuclei and 
gigantocellular reticular nucleus; in stage 3, LB pathology enters into midbrain, which 
presents in SNpc and basal forebrain; in stage 4, the SNpc neurons are severely destructed, 
while the mesocortex, the allocortex, the subnuclei of the thalamus, and hippocampal 
formation are also affected; in stage 5, LBs start to appear in higher order association cortex 
and prefrontal neocortex; in stage 6, LB pathology invades the entire neocortex, affecting the 
first-order sensory and motor areas (Jellinger 2018).  
Based on the progression of LB pathology along anatomic routes and in a stereotypical 
spatiotemporal pattern, the hypothesis that a prion-like spreading of α-synuclein pathology 
might contribute to PD pathogenesis was proposed (Masuda-Suzukake et al. 2013). However, 
it is still unclear whether LBs and Lewy neurites are neuroprotective or neurotoxic, and to 
what extent they contribute to clinical symptoms, as some individuals have severe α-synuclein 
pathology at autopsy but without any clinical symptoms (Kim et al. 2014).  
1.1.4 Genetic risk factors of PD  
The majority of diagnosed PD cases are sporadic. However, approximately 5–10% PD are 
heritable forms, and several genes are reported which can cause monogenic types of PD, for 
example, mutations in SNCA (Polymeropoulos et al. 1996), LRRK2 (Leucine-rich repeat 
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kinase 2) (Brice 2005), VPS35 (Vacuolar Protein Sorting-Associated Protein 35) (Zimprich et 
al. 2011), Dnajc13 (DnaJ Heat Shock Protein Family (Hsp40) Member C13) and GBA 
(glucosylceramidase gene) (Nalls et al. 2014) can cause autosomal-dominant PD forms; 
mutations in PARKIN (Parkin RBR E3 Ubiquitin Protein Ligase) (Lücking et al. 2000), 
PINK1 (PTEN Induced Kinase 1) (Li et al. 2005) and DJ-1 (Protein Deglycase) (Pankratz et 
al. 2006) are accounted for autosomal recessive PD forms. Besides, many other genes which 
are identified from genetic linkage analysis and GWAS have shown contribution effects in 
sporadic PD. These genes are widely located in over 40 loci, e.g., microtubule-associated 
protein tau (MAPT), N-acetyltransferase 2 (NAT2), Peroxisome proliferator-activated 
receptor-γ (PPARγ), human leukocyte antigen gene complex (HLA-DRA), and Apolipoprotein 
E (APOE) (Domingo and Klein 2018; Billingsley et al. 2018). These genetic risk factors 
provide important clues for understanding the potential mechanisms and pathways in the 
neuropathology of PD. So far, it is known that these genetic risk factors are involved in α-
Synuclein pathology, mitochondrial dysfunction, oxidative stress and neuroinflammation. 
1.1.5 α-Synuclein pathology in PD 
α-Synuclein (SNCA) is a 14-kDa protein which is mainly located in presynaptic terminals and 
highly soluble under normal condition. The physiological function of α-synuclein is not fully 
understood so far. It is suggested that α-synuclein plays a role in SNARE complex assembly, 
synaptic vesicle release and lipid binding (Burré et al. 2010; Bendor et al. 2013; Logan et al. 
2017). α-Synuclein is the major constituent of LBs which are found in many 
neurodegenerative diseases, such as PD, DLB (dementia with Lewy bodies) and MSA 
(multiple system atrophy).  
SNCA was the first discovered gene in autosomal dominant PD. Several point mutations of α-
synuclein, like A30P (Krüger et al. 1998), A53T (Gispert et al. 2003), E46K (Zarranz et al. 
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2004), H50Q (Appel‐Cresswell et al. 2013) and G51D (Lesage et al. 2013) can cause 
autosomal dominant PD, as well as the genomic duplication (Chartier-Harlin et al. 2004) and 
triplication (Singleton et al. 2003) of SNCA that significantly increase the protein expression. 
Furthermore, GWAS revealed that single-nucleotide polymorphisms in SNCA which lead to 
the higher α-synuclein expression can also increase the risk for sporadic PD (Simon-Sanchez 
et al. 2009; Nalls et al. 2014; Soldner et al. 2016). This further implicates the crucial role of α-
synuclein in PD pathology.  
Mutations of α-synuclein which favor misfolding or overexpression can accelerate its 
oligomerization and fibrillation (Bartels et al. 2011; Nuber et al. 2018), which leads to the 
endoplasmic reticulum (ER) and oxidative stress, mitochondrial dysfunction and cell death 
(Martinez-Vicente et al. 2008; Kaushik and Cuervo 2015). 
Misfolded and aggregated α-synuclein are assumed to be degraded mainly via chaperone-
mediated autophagy (CMA) and macroautophagy (Xilouri et al. 2013; Michel et al. 2016), 
both of which belong to lysosomal autophagy system (LAS). Many LAS related gene 
mutations are also associated with PD, for example, VPS35 (vacuolar protein sorting-35), 
LRRK2 (Leucine-rich repeat kinase 2) and GBA (glucocerebrosidase), which indicates that 
impairment of either degradation pathway can contribute to α-synuclein pathology (Tsika et 
al. 2014; Volpicelli-Daley et al. 2016).  
1.1.6 Endoplasmic reticulum (ER) stress and response in PD 
The ER is the major organelle for protein folding in eukaryote cells. Misfolded proteins can 
cause ER stress (Hetz 2012) and UPR pathway activation. UPR is designed as a protein 
quality control system which detects misfolded proteins by utilizing three different sensor 
protein-transcription factor pairs, IRE1α (inositol requiring kinase 1α)/XBP1 (X-Box binding 
protein-1), PERK (protein kinase RNA-like ER kinase)/ATF4 ( activating transcription factor 
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4) and ATF6α (activating transcription factor 6) (Jiang et al. 2015). The activation of 
downstream pathways effectively reduces protein translation and induces ER chaperones 
activities to clear misfolded proteins via autophagy or the ER-associated degradation (ERAD) 
pathway (Hetz et al. 2011). ER stress is involved in the pathogenesis of PD, mostly caused by 
misfolded and aggregated α-synuclein (Matus et al. 2011), which accumulates in the ER of α-
synuclein transgenic mice (Colla et al. 2012). Several postmortem studies also showed that 
ER stress and active UPR pathways were present in SNpc dopaminergic neurons, and many 
ER chaperones like BiP (binding immunoglobulin protein) and PDIp (protein disulfide-
isomerase) were also upregulated in PD patients as reported previously (Hoozemans et al. 
2012; Selvaraj et al. 2012; Colla et al. 2012). Furthermore, in the ATF6α knockout mouse 
model, an exacerbated dopaminergic neuronal loss was observed after MPTP treatment, when 
compared with control mice (Egawa et al. 2011). This suggests that ER stress and active UPR 
pathways may be neuroprotective. However, chronic ER stress when UPR fails to restore 
protein homeostasis can induce cell death through apoptosis (Urra et al. 2013). For instance, 
in the 6-OHDA mouse model, activation of UPR under ER stress was protective at early 
stages, whereas chronic UPR activation was shown to result in apoptosis (Mercado et al. 
2015).  
IRE1α is a transmembrane ER stress sensor protein. Upon activation either by 
phosphorylation or dimerization, IRE1α eliminates a 26-nucleotide intron of the transcription 
factor XBP1 mRNA. This unconventional splicing leads a shift of the reading frame and 
results in the active form, XBP1s transcription factor. XBP1s activates ER chaperones 
(Grp78/BiP, Grp58, Grp94) and ERAD components EDEM (ERAD-enhancing a-
mannosidase-like proteins) and HRD1 (HMG-CoA reductase degradation protein 1) to refold 
and degrade misfolded proteins (Valdés et al. 2014). Depending on activation pathways, 
durations and downstream pathways, XBP1s can be either protective or toxic. It has been 
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shown that overexpression of XBP1s is neuroprotective in MPP
+
 treated dopaminergic 
neurons (Sado et al. 2009a) and in the 6-OHDA mouse model, whereas down-regulation of 
XBP1 leads to chronic ER stress and neuronal death (Valdés et al. 2014). However, recent 
studies showed that XBP1s activation promoted pathogenesis in many neurodegenerative 
diseases, like AD (Duran-Aniotz et al. 2017a), PD (Hetz and Mollereau 2014), Prion (Moreno 
et al. 2013) and Huntington’s disease (Urra et al. 2013). Furthermore, inhibition of the 
IRE1/XBP1 pathway by β-asarone showed therapeutic effects in the 6-OHDA rat model 
(Ning et al. 2016).  
1.2 Neuroinflammation in PD 
1.2.1 Microglia origins 
Microglia account for approximately 10 – 15% of total cells in brain (Lawson et al. 1990; 
Mittelbronn et al. 2001) and are derived from primitive yolk sac myeloid progenitors which 
enter the brain during early development (Alliot et al. 1999; Giunti et al. 2014). As the 
resident macrophage cells in CNS, microglia have multiple crucial functions which are 
involved in neural maintenance, pathogen response and promoting repair, and these functions 
can be altered by interactions with astrocytes, neurons, the blood-brain-barrier (BBB) and 
migrated T-cells (Stevens et al. 2007; Tremblay et al. 2010; Olah et al. 2011; Paolicelli et al. 
2011; González et al. 2014). Microglia have physiological and pathological conditions.  
1.2.2 Resting microglia  
Under physiological conditions, microglia show a ramified morphology. Resting microglia 
keep inspecting the microenvironment and receiving signals from neurons or astrocytes 
(Davalos et al. 2005; Schmid et al. 2009; Nimmerjahn et al. 2005) via CX3CL1, 
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neurotransmitters, neurotrophins or CD22. Resting microglia is mainly regulated by TREM2 
(triggering receptor also expressed on myeloid cells-2), Irf8 (Interferon regulatory factor 8), 
Runx1 (Runt-related transcription factor 1), chemokine CX3CR1 (CX3C chemokine receptor 
1) and CD200R (Cell surface glycoprotein CD200 receptor) (Kierdorf and Prinz 2013). Also, 
resting microglia express a high level of microRNA-124, which further suppresses the 
activation of microglia by expression CD46 (cluster of differentiation 46), MHC-II (major 
histocompatibility complex-II) and CD11b (cluster of differentiation molecule 11B) (Conrad 
and Dittel 2011). 
1.2.3 Activated Microglia phenotypes 
Microglia, when activated by different stimuli in vitro, can exert numerous functionally 
distinct activated phenotypes, which can be divided into two polarized phenotypes, named M1 
and M2. 
1.2.3.1 The M1 phenotype 
The M1 phenotype, which is also termed “classical state”, is an immediate response to injury 
and infection, acting in the first line to defense against pathogens. The key features of the M1 
phenotype are released pro-inflammatory factors and presentation of cell surface markers 
which are associated with pro-inflammatory and pro-killing functions (Block et al. 2007; Gao 
et al. 2003). M1 associated pro-inflammatory cytokines include IL(interleukin)-1β, IL-6, IL-
12, IL-17, IL-18, IL-23, TNF-α (tumor necrosis factor-α), IFN-γ (Interferon-γ) and NO (nitric 
oxide). M1 associated pro-inflammatory chemokines include CCL2 (C-C motif chemokine 
ligand 2) and CXCL10 (C-X-C motif chemokine 10) (Loane and Byrnes 2010; Mahad and 
Ransohoff 2003; Kawanokuchi et al. 2006; Nakagawa and Chiba 2015; Benarroch 2013). Cell 
surface markers presented in the M1 phenotype are MHC-II (major histocompatibility 
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complex-II), CD86 (Cluster of Differentiation 86), CD16/32, iNOS (Induced nitric oxide 
synthase ), COX-2 (cyclo-oxygenase 2) (Chhor et al. 2013; Franco and Fernandez-Suarez 
2015), RNS (reactive nitrogen species), ROS (reactive oxygen species) and prostaglandin E2 
(Benarroch 2013; Nakagawa and Chiba 2015).  
In experimental models, the M1 phenotype can be classically induced by microbe-associated 
molecular pattern molecules, such as IFN-γ and LPS (Lipopolysaccharide), as depicted in 
Figure 1.1 (Loane and Byrnes 2010; Boche et al. 2013). 
IFN-γ activates the M1 phenotype by JAK (Janus kinase)/STAT (Signal Transducer and 
Activator of Transcription protein) signaling pathway. First, IFN-γ activates IFN-γ receptors 
(1 and 2), and the activated receptors then lead to JAK1/2 activation, which then further 
phosphorylate and activate STATs and IRFs (interferon regulatory factors). This signaling 
cascade can stimulate the expressions of several pro-inflammatory cytokines, chemokines and 
other related genes (Hu and Ivashkiv 2009; Boche et al. 2013). 
Another M1 stimulus, LPS, activates the M1 phenotype via TLRs (toll-like receptors). LPS 
first binds to TLR4 along with coupled receptors: LY96 (Lymphocyte antigen 96) and CD14. 
The binding then stimulates the activation of transcription factors, which include NFKβ 
(nuclear factor kappa-light-chain-enhancer of activated B cells), STAT5, AP1 (Activator 
protein 1) and IRFs (Hu and Ivashkiv 2009). The TLRs activation cascades, through MyD88 
(Myeloid differentiation primary response 88) or TRIF (TIR-domain-containing adapter-
inducing interferon-β), cause transcriptional upregulation of M1-associated cytokines and 
chemokines (Takeda and Akira 2004). 
Furthermore, GM-CSF (Granulocyte-modifying colony-stimulating factor) can also activate 
the M1 phenotype. However, unlike the others, it was reported that GM-CSF could induce 
pleomorphic activations with both M1 and M2 elements presented (Weisser et al. 2013). 
Since then, it has increasingly been recognized that the distinction between M1 and M2 
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activation state is oversimplified and that there is a spectrum of overlapping microglia and 
macrophage activation states.  
1.2.3.2 M2 phenotypes 
M2 phenotypes, also named “alternative activation”, are associated with various events 
including anti-inflammation, tissue repair and extracellular matrix reconstruction. M2 
phenotypes can produce several anti-inflammatory cytokines (e.g., IL-4, IL-10 and IL-13) to 
suppress the pro-inflammatory cytokines (e.g.,IL-8, IL-6, TNF-α and IFN-γ). Besides, they 
also produce extracellular matrix proteins and neurotrophic factors, such as TGF-β 
(Transforming growth factor beta), IGF-1(Insulin-like growth factor 1) and other substances 
(Butovsky et al. 2005; Zhou et al. 2012). The typical markers for tissue reconstruction during 
M2 activation include arginase 1 (Arg1), chitinase-like protein (Ym1), found in inflammatory 
zone (Fizz1) and peroxisome proliferator activated receptor (PPAR) (Ponomarev et al. 2007; 
Michelucci et al. 2009). 
Based on the different activation mechanisms and cytokines released, M2 phenotypes can be 
further divided into 3 subforms: M2a, M2b and M2c (as shown in Figure 1.1).  
The M2a phenotype can be activated by IL-4 or IL-13 when IL-4/IL-13 binds to its receptor 
pair (IL-4 binds to the IL4Rα receptor and IL-13 binds to the IL13Rα1 receptor). Downstream 
of the receptors activation, JAK1 and JAK3 are stimulated and then activate STAT6, which 
further stimulate M2a-associated genes transcription, such as CD206 (mannose receptor), 
SOCS3 (suppressor of cytokine release 1) and SRs (scavenger receptors). M2a secretes 
polyamines and IL-10, which are associated with tissue repair and phagocytosis (Martinez et 
al. 2013; Lu et al. 2013).  
The M2b phenotype is not fully understood since it can produce both pro- and anti-
inflammatory cytokines (Bell-Temin et al. 2015). This phenotype is normally activated by 
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immune complexes through the engagement of TLRs and IL-1 receptor. The activated TLRs 
then interact with Fcγ receptors and then bind to Immunoglobulin G to induce the M2b 
phenotype. The M2b phenotype secretes high amounts of IL10, as well as some pro-
inflammatory cytokines at a modest level. CD86 is also a marker for M2b which is highly 
expressed on the cell surface. M2b is associated with up-regulated phagocytosis and 
modulation of inflammatory response (Sánchez‐Mejorada and Rosales 1998; Takai 2002; 
Edwards et al. 2006). 
Another phenotype, M2c, is activated by IL-10, TGF-α and glucocorticoid hormones. First, 
IL-10 binds to IL-10 receptors (R1 and R2), which then translocate STAT3 into the nucleus 
and activate JAK1. The M2c phenotype suppresses many M1-associated pro-inflammatory 
cytokines (Franco and Fernandez-Suarez 2015; Michell-Robinson et al. 2015) and is 
associated with tissue regeneration, de-activation of M1/Th1 immune responses and 
extracellular matrix repairing (Fiorentino et al. 1989; Glocker et al. 2009; Harms et al. 2013). 
It is important to note that activated microglia display features of both M1 and M2 phenotypes 
(Vogel et al. 2013; Martinez and Gordon 2014). The continuum of M1 and M2 phenotypes 
could be observed in some other neurodegenerative diseases, such as MS (Multiple Sclerosis) 
(Zhang et al. 2011) and acute CNS injury (Zhang et al. 2012; Kigerl et al. 2009). In spinal 




) phenotypes were co-
localized at injury sites (Shechter et al. 2009; Shechter et al. 2013).  
The M1/M2 classification of activated microglia provides a basic understanding of the protein 
expression and the immune response states in vitro. However, this classification which is 
mainly based on the distinct stimuli and released factors is considered as over-simplistic. As 
discovered from both mouse and human tissue, Single-cell RNA sequencing analysis of 
microglia also showed that the profiles of each microglia cell were highly diverse in a 
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dynamic homeostasis state in vivo (Li et al. 2019; Masuda et al. 2019). In human microglia, 3 
different clusters of transcriptome profiles were identified in healthy human tissues, as 
“homeostatic microglia”, whereas another 4 clusters were found in early MS patients tissues, 
as “DAM”. Each cluster has more than one or two markers for identification, which indicates 
that the microglia are a complex mixture of many different phenotypes.  
 
Figure 1.1 Potential activation and response signaling pathways of M1 and M2 states 
Figure is adapted from (Subramaniam and Federoff 2017)  
 
1.2.4 Microglia activation in PD 
Although maybe not the initiator, neuroinflammation is implicated to play a crucial role in 
PD. Activated microglia are acting as the major component of neuroinflammation in the CNS. 
The classical activation of microglia, the M1 phenotype and its pro-inflammatory effects have 
been widely studied in PD patients and PD animal models. It was first shown by immune- 
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histochemistry (IHC) that microglia were activated in SN and striatum in post-mortem tissue 
of PD patients (McGeer et al. 1988). Several pro-inflammatory cytokines were also elevated 
in PD patients serum and cerebrospinal fluid (CSF), such as MHC-II, TNF-α and IL-6, and 
the elevated cytokine levels correlated with severity of motor deficits (Boka et al. 1994; 
Imamura et al. 2003). Activated microglia in brains of PD patients are suggested to exacerbate 
dopaminergic neuronal loss and the neurodegeneration process (Hofmann et al. 2009; Scalzo 
et al. 2010).  
In PD, activation of microglia is assumed to be caused by neuromelanin (Wilms et al. 2003b; 
Zhang et al. 2013), environmental toxins (Rotenone, Paraquat, MPTP) (Goldman 2014), 
misfolded and aggregated α-synuclein (Zhang et al. 2005b; Couch et al. 2011; Acosta et al. 
2015). Studies suggest that aggregated α-synuclein released from dying or dead dopaminergic 
neurons can directly induce microglia activation, mainly through interactions with TLR2 or 
TLR4 receptors (Béraud et al. 2011; Fellner et al. 2013; Kim et al. 2013). Activated microglia 
increase NADPH oxidase, ROS and pro-inflammatory cytokines, which can in turn further 
promote α-synuclein misfolding and aggregation (Gao et al. 2008), suggesting that the two 
processes engaged in a self-aggravating cycle (Hirsch and Hunot 2009; Ransohoff 2016).  
Recent GWAS studies also linked several genetic risk factors of PD to neuroinflammation, 
such as LRRK2 (Schapansky et al. 2014; Akundi et al. 2011; Gillardon et al. 2012; Moehle et 
al. 2012; Ma et al. 2016), HLA-DR (Ahmed et al. 2012; Nalls et al. 2014; Wissemann et al. 
2013), PINK1 (Akundi et al. 2011) and DJ-1 (Castro et al. 2010). High expression levels of 
these genes can be found in myeloid cells in PD animal models. It has also been reported that 
knockdown, knockout, or inhibition these genes in several animal models attenuate M1 
microglia inflammatory responses and show protective effects on dopaminergic neuronal loss 
(Waak et al. 2009; Moehle et al. 2012; Hamza et al. 2010; Kim et al. 2012). 
  Introduction 
15 
 
1.2.5 Therapeutic manipulation of microglia in PD 
Inhibition of microglia activation can attenuate or halt neuroinflammation in multiple PD 
models. For example, in the MPTP mouse model of Parkinsonism, minocycline
®
, a 
tetracycline antibiotic, inhibited iNOS expression and NO-induced microglial activation (Du 
et al. 2001); ibuprofen
®
, one of the nonsteroidal anti-inflammatory drugs (NSAID), decreased 
the dopamine turnover and inhibited cyclooxygenases (Cox) (Świątkiewicz et al. 2013); 
bioflavonoid pycnogenol
®
, an effective scavenger of ROS from maritime pine bark (Khan et 
al. 2013), and peptide carnosine
®
, a natural imidazolic dipeptide, also showed reduced 
neuroinflammation and attenuated oxidative stress (Tsai et al. 2010). However, most of these 
anti-inflammatory drugs failed to show benefits in clinical trials with PD patients (Rees et al. 
2011; Gao et al. 2011; Becker et al. 2011; Keller et al. 2011; Pena-Altamira et al. 2016). In 
the α-syn transgenic model, several other anti-inflammatory drugs also attenuated 
neuroinflammation and improved behavioral performance, e.g., NF-κB modulator 
hypoestoxide (Kim et al. 2015) and NF-κB inhibitor lenalidomide (Valera et al. 2015). 
Furthermore, AZD1480 (an ATP competitive inhibitor of JAK2 kinase) and FK506 (= 
Tacrolimus or fujimycin), were also able to reduce neuroinflammation and dopaminergic 
neurodegeneration in the AAV α-syn overexpression rat model, by inhibiting STAT activation 
(Qin et al. 2016) and preventing calcineurin phosphorylation (Van der Perren et al. 2015; Qin 
et al. 2016). Besides, AZD1480 and FK506 can easily cross the BBB (Plimack et al. 2013; 
Uchino et al. 2002). However, AZD1480 failed the phase I study in myelofibrosis patients due 
to reversible neurological toxicity (Verstovsek et al. 2015). These results indicate that the 
inhibition of microglia activation may provide therapeutic effects in PD (Mascarenhas et al. 
2014; Wong and Krainc 2017). However, this therapy by globally blocking microglia 
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activation could also impair host response to pathogens in general and increase infection risk 
(Kwon et al. 2014; Varley et al. 2013). 
Blocking the interaction of pro-inflammatory cytokines with its receptors has been evaluated 
in PD animal models, for example, anti-TNF-α therapy. Binding TNF-α with neutralizing 
antibodies (adalimumab), treatment with TNF decoy receptors (etanercept), or AAV injection 
of dominant negative TNF can attenuate dopaminergic neuron loss in 6-OHDA rat model 
(Braun et al. 2007; McCoy et al. 2008; Harms et al. 2011; Frankola et al. 2011). Anti-TNF-α 
therapy was successfully used to reduce systemic inflammation in inflammatory bowel 
disease (IBD), including Crohn's disease and ulcerative colitis over the last decade (Neurath 
2014). Interestingly, a recent retrospective cohort study revealed that the incidence of PD was 
28% higher in IBD patients than non-IBD controls. Moreover, among these IBD patients, 
anti-TNF therapy showed a 78% reduction in the incidence of PD compared with non-treated 
patients (Peter et al. 2018). The beneficial effect of anti-inflammatory treatments was 
supported by several other retrospective cohort studies in different countries (Steeland et al. 
2018; Weimers et al. 2018; Wu et al. 2018), which strongly indicate that reducing systemic 
inflammation by anti-TNF-α therapy may provide therapeutic benefits for PD patients. 
However, large molecules used for counteracting TNF-α are restricted by BBB permeability, 
which limits the clinical application. The recently developed nanobody TROS (TNF Receptor 
One Silencer) (Steeland et al. 2015) which can easily cross the BBB may be a promising 
treatment option for PD, since it showed reduced brain inflammation in APP/PS1 AD mouse 
model by blocking TNFR1 (TNF signaling receptor 1) (Steeland et al. 2018). 
Another promising strategy is to shift activated microglia from pro- to anti-inflammatory 
state. It has been reported that molecules such as IL-10 and beta interferons can promote the 
transition of pro- to anti-inflammatory microglia activation state and hence be promising for 
PD treatment. For instance, injection of AAV expressing human IL-10 into MPTP pre-treated 
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mice decreased levels of pro-inflammatory mediators including IL-1β, IL-6, TNF-α and 
iNOS. In addition, it attenuated the loss of striatal dopamine and the decrease of tyrosine 
hydrosylase (Schwenkgrub et al. 2013; Joniec-Maciejak et al. 2014). 
Pioglitazone, a PPARγ (peroxisome proliferator activated receptor-gamma) agonist, is also a 
promising molecule to induce the transition of M1 to M2 phenotype (Zhao et al. 2016b). 
PPARγ is a transcription factor in nuclear receptor superfamily that regulates many cellular 
functions which include lipid metabolism, cell differentiation and inflammatory response 
(Jafari et al. 2007; Kemp et al. 2012) . PPARγ activation by Pioglitazone has been tested in 
many psychiatric and neurodegenerative diseases where neuroinflammation is involved (Sato 
et al. 2011; Christine 2015; Liu et al. 2017; Machado et al. 2018). Administration of 
pioglitazone in the MPTP mouse model decreased proinflammatory microglia activation as 
well as iNOS- and NO-mediated toxicity in the striatum and substantia nigra (Quinn et al. 
2008; Dehmer et al. 2004; Barbiero et al. 2014). However, Pioglitazone treatment failed to 
modify neuroinflammation in early PD patients in a recent clinical trial (Simuni et al. 2015) 
and also failed to lower the incidence of PD diagnosis in a large Taiwanese cohort of PD 
patients with diabetes mellitus (Wu et al. 2018).  
Few FDA approved drugs for Multiple Sclerosis (MS) treatment, such as Glatiramer acetate 
(Giunti et al. 2014; English and Aloi 2015) and Dimethyl fumarate (DMF) (Campolo et al. 
2017) also showed neuroprotective effects in the MPTP mouse model, presumably by shifting 
activated microglia from M1 to M2 state and upregulation of GDNF expression. 
Besides, several recently reported potential therapeutic drugs in PD are also associated with 
immune response in PD animal models, e.g., treatment with inhibitors for HMGB1 (Shin et 
al. 2014), GSK3β (Morales-García et al. 2012; Kondratiuk et al. 2013; Prati et al. 2015) , 
HDACs (Faraco et al. 2009; Wang et al. 2015b) and activators of AMPK (Zhu et al. 2015; 
Wang et al. 2015a).  
  Introduction 
18 
 
Taken together, it is believed that shifting activated microglia from pro- to anti-inflammatory 
state would restore homeostasis and may have promising therapeutic value in PD and other 
neurodegenerative diseases. 
1.3 Animal models of Parkinson’s disease 
An ideal animal model of PD should present selective and gradual loss of dopamine neurons 
during aging, obvious motor deficits, α‐synuclein and Lewy body pathology and 
neuroinflammation (Beal 2001). Rodents and primates are the most studied species used in 
PD research, because of the similarity of gene homologs and brain morphology to human 
(Potashkin et al. 2011). In humans, both genetic and environmental factors, as well as 
interactions between them contribute to PD pathogenesis. Similarly, animal models of 
Parkinsonism can also be divided into genetic models, neurotoxin-based models and 
combination of both (Dawson et al. 2010; Dawson et al. 2018).  
Until recently, many transgenic rodents models have been generated with different promoters, 
mostly focused on SNCA (α‐synuclein), as well as other genes including LRRK2 (leucine‐
rich repeat kinase 2), Parkin (RBR E3 ubiquitin protein ligase), PINK1 (PTEN‐induced 
putative kinase 1) and DJ‐1 (Lee et al. 2012; Poewe et al. 2017; Yun et al. 2018). Most of α–
synuclein transgenic rodents models (A30P, A53T and E46K) exhibit aggregated α-synuclein 
and show substantial neurodegeneration (McDowell and Chesselet 2012). However, the 
absence of DA neurons loss is considered as a major limitation of these models (Visanji et al. 
2016). In contrast, conditional or cell-type-specific overexpression of α-synuclein mutants 
results in DA neuronal degeneration (Koprich et al. 2017). Lentiviruses or Adeno-associated 
Viruses (AAV) overexpression of wild type and/or mutated α-synuclein is widely used for α-
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synucleinopathy investigation. It also causes DA neuronal degeneration if SN is the injection 
area (Van der Perren et al. 2014; Oliveras-Salvá et al. 2013).  
The most widely utilized neurotoxin-based rodents models are two potent complex I 
inhibitors, 6‐hydroxydopamine (6‐OHDA) (Iglesias-González et al. 2012) and 1‐methyl‐
1,2,3,6 tetrahydropyridine (MPTP) (Martinez and Greenamyre 2012). Besides, pesticides 
which induce mitochondrial dysfunction and oxidative stress are also used to mimic PD, such 
as paraquat and rotenone (Tanner et al. 2011). 
1.3.1 The MPTP mouse model of Parkinsonism 
1.3.1.1 Mechanisms of MPTP  
The MPTP mouse model is the best characterized neurotoxin‐based animal model which 
mimics many hallmarks of PD, such as dopaminergic neuron loss in the SNpc and striatum, 
oxidative stress, neuroinflammation and motor deficits (Dauer and Przedborski 2003). MPTP 
was first discovered to induce Parkinsonism in 1982. 7 US drug-users rapidly emerged with 
motor symptoms similar to those observed in Parkinson’s disease after self-intoxication of 1-
methyl-4-phenyl-4-propionoxypiperidine (MPPP) which was contaminated with MPTP, as a 
byproduct of MPPP synthesis (Langston 1985; Langston et al. 1983). These patients 
responded to L-Dopa treatment. MPTP was found to selectively destroy dopaminergic 
neurons in the SNpc (Meredith and Rademacher 2011). In the subsequent years after 
discovering its neurotoxic potential in humans, neurotoxic effects of MPTP were tested in 
primates, cats, and several rodents (Kopin and Markey 1988; Jenner 2003; Wichmann and 
DeLONG 2003). Interestingly, for unknown reasons, rats are highly resistant to the toxicity of 
MPTP, and different mouse strains also shows widely varieties in their sensitivity to MPTP  
(Mitra et al. 1994; Riachi and Harik 1988; Hamre et al. 1999). MPTP has been widely used 
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via subcutaneous, intraperitoneal, intravenous or intramuscular injection into mice and 
monkeys to mimic motor symptoms of PD. The mouse is the most widely used species for 
MPTP studies (Schmidt and Ferger 2001). 
MPTP itself is not toxic. After crossing the BBB, MPTP is metabolized by monoamine 
oxidase (MAO)-B in glial cells to the unstable 1-methyl-4-phenyl-2,3-dihydropyridium 
(MPDP
+
), which is followed by deprotonation to generate its active metabolite, MPP
+
 
(D'Amato et al. 1987; Friedman and Mytilineou 1990). MPP
+
 is preferentially taken up into 
dopaminergic neurons through the dopamine transporter (DAT) and is thus selectively toxic 
to dopaminergic neurons (Gainetdinov et al. 1997; Bezard et al. 1999). Once MPP
+ 
enters the 
cell, it inhibits complex I of the mitochondrial electron transport chain (ETC), which leads to 
reduced ATP synthesis and increased oxidative stress, as shown in Figure 1.2 (Nicklas et al. 
1985; Pennathur et al. 1999). MPP
+
 toxicity results in cell death which induces pro-
inflammatory responses with increased levels of pro-inflammatory cytokines, such as IL-6, 
IFN-γ and TNF-α. This pro-inflammatory environment further promotes neurodegeneration 
(Członkowska et al. 1996; Smeyne and Jackson-Lewis 2005). Blocking TNF receptors by 
neutralizing antibodies could protect against MPTP-induced neurodegeneration (Sriram et al. 
2002; Mount et al. 2007). Therefore, the MPTP model is useful for studying oxidative stress, 
mitochondrial dysfunction, inflammatory reactions and motor performance in Parkinsonism. 
1.3.1.2 Acute versus subacute and chronic MPTP models 
It is important to note that the dopaminergic neuronal loss is related to the dose and schemes 
of MPTP treatment (Schmidt and Ferger 2001). The MPTP mouse model can be categorized 
into three different schemes: the acute model, the subacute model and the chronic model. The 
three different schemes mimic different aspects and stages of PD and thus are valuable for PD 
research. 
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The acute model was the first invented model, in which C57BL/6 mice received an 
intermediate dose of MPTP (4 × 15-20mg/kg body weight) intraperitoneally (i.p.) over 8 h 
with 2 h intervals. In this model, mice display extensive (40-50%) loss of dopaminergic 
neurons in SNpc 12 h after administration and rapid cell death which is mainly due to necrosis 
(Jackson-Lewis et al. 1995) (Sonsalla and Heikkila 1986). This model is widely used to 
understand the neurotoxic process of MPTP in the brain. However, the necrotic cell death 
does not mimic the slowly progressive pathology in human. Therefore, the subacute and 
chronic models were developed to mimic human PD better. In the subacute scheme, 30 mg/kg 
body weight of free base MPTP is i.p. injected once daily for 5 consecutive days, and the 
subacute MPTP treated mice show progressive loss of SNpc DA neurons and striatal DA 
which is mainly due to apoptosis. The degeneration of dopaminergic fibers in the striatum 
takes place until 7 days after the last MPTP administration, which is named “delayed 
degeneration”, and the regeneration of dopaminergic fibers starts from 90 days after the last 
MPTP administration (Tatton and Kish 1997; Vila et al. 2000). Since LBs pathology is absent 
in both acute and subacute models, chronic blocking complex I was thought to be necessary 
for LB presence. Thus multiple chronic modes of MPTP application were tested and the 
schemes vary from weeks to months, including different injection models (low MPTP doses 
injected 2 or 3 days/injection over weeks or months) or constant MPTP subcutaneous 
pumping models. However, most of the chronic MPTP treatment failed to achieve LBs 
(Gibrat et al. 2009; Purisai et al. 2005). Also, the SNpc dopaminergic neuronal loss was very 
slow and mild in this model as shown in several studies (Fornai et al. 2005). It was even 
reported that the dopaminergic neuron loss was presented only with extra-treatment of 
probenecid in the chronic model, which is also neurotoxic itself and used to reduce renal 
elimination of MPTP (Alvarez‐Fischer et al. 2013; Alvarez‐Fischer et al. 2008). Furthermore, 
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the nigrostriatal degeneration was much lower than in PD patients (Meredith and Rademacher 
2011; Goldberg et al. 2011). Based on that, this model is mainly used to mimic the very early 
stage of PD and provides a longer observation period to investigate the pathogenesis before 
motor symptoms present (Philippens 2018). 
1.3.1.3 Behavior phenotypes in MPTP models 
The open field box test with infrared beams equipped is widely used to evaluate the general 
movement of the mice shortly after MPTP intoxication. MPTP injected mice normally show 
the paucity of movement with longer time for traveling the same distance (Sedelis et al. 
2000), but the paucity may disappear over time (Dauer and Przedborski 2003). Another 
widely used method is the rotarod test, where trained mice stay on a speeding rod until they 
fail to catch up the speed. MPTP injected mice showed shorter latency to fall off the rod 
compared with control mice in some studies (Luchtman et al. 2009), while other studies failed 
to detect the difference (Meredith and Kang 2006).  
There are several tests focusing more on the forelimbs activities to detect the subtle 
degeneration of the dopaminergic system (Ogawa et al. 1985; Chan et al. 2007; Haobam et al. 
2005), for example, MPTP treated mice have shown behavior deficits in the pole test (Chan et 
al. 2007), in the grid test (Tillerson and Miller 2002) and in the forelimb stepping test (Blume 
et al. 2009).  
1.3.1.4 Advantages and disadvantages of MPTP model 
MPTP is a potent complex I inhibitor which can cause Parkinsonism both in human and 
rodents. It induces the loss of DA neurons in SNpc, axons degeneration and eventually the 
loss of DA in the striatum, in a relatively slow and progressive way, which mimics the 
occurring of PD during aging. 
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The MPTP model of Parkinsonism has many advantages compared with other neurotoxin-
based models. For example, in the 6-hydroxydopamine (6-OHDA) animal model, 6-OHDA 
has to be intracerebrally injected because it can not pass the BBB. Besides, 6-OHDA can not 
only impair DA neurons, but also target noradrenergic transporters and induce 
neurodegeneration in other regions (Luthman et al. 1989; Meredith and Rademacher 2011). 
The other two widely used pesticides-based models, rotenone (Fleming et al. 2004) and 
Paraquat (McCormack et al. 2002; Miller 2007), also show dopaminergic degeneration and 
intracellular inclusions which resemble LBs in some studies. However, large variabilities with 
high mortality issues have limited its further application in animals (Sherer et al. 2003; Miller 
2007).  
It is essential to mention that as an animal model, MPTP model also has some limitations. 
First, MPP
+
 solely inhibits complex I activity in dopamine transporter-expressing cells, like 
dopaminergic neurons, lacking in mimic the systematic impairments in PD (Betarbet et al. 
2002). Second, MPTP model fails to mimic the advanced stage of PD, when the non-
dopaminergic neurodegeneration and non-motor symptoms become dominate. Third, MPTP 
model shows no LBs pathology, which is one of the most important pathological hallmarks in 
PD. Furthermore, the acute scheme of MPTP treatment is the least frequently used model, 
since it has severe mortality rate and fails to mimic the progressive pathogenesis of PD, 
whereas subacute and chronical MPTP treatment overcome this limitation (Dauer and 
Przedborski 2003).  
So far, there is no perfect model for PD research. Neurotoxin-based models are more useful 
for disease-modifying therapies, as it closely mimics the PD pathology, whereas transgenic 
animal models are more suitable for investigating the specific mechanisms and processes of 
neurodegeneration in PD.  




Figure 1.2 Schematic mechanisms of MPTP toxicity in CNS 
Step 1: transport MPTP into CNS via BBB; Step 2: MPTP is converted into MPP
+
 by MAO-B in glial 
cells, which leads to gliosis, induction of cytokines, and activation of M1 microglia with pro-inflammatory 
effects; Step 3: MPP
+
 is released from the Astrocytes through OCT-3 transporter; Step 4: MPP
+
 is 
transported into the dopaminergic neuron through the DA transporter; Step 5: Once enters the 
dopaminergic neurons, MPP
+
 diffuses into the mitochondria and inhibits complex I of electron transport 
chain, resulting in ATP and NAD depletion; Step 6: MPP
+
 produces peroxynitrite (OONO-), which impairs 
TH activity, increases dopamine metabolisms and also nitrates many other mitochondrial components; Step 
7: MPP
+
 is transported from the cytoplasmic space into synaptic vesicle by vesicular monoamine 
transporter (VMAT); Step 8: Releasing of dopamine into extracellular space caused by cellular ATP 
depletion leads to dopamine oxidation and hydroxyl radical formation, which further results in cell death; 
Step 9: increased dopamine in excellular space upregulates hemeoxygenase-1 (HO-1) expression, a rate-
limiting enzyme for heme degradation. HO-1 is postulated to be protective in dopaminergic neurons. 
Figure is adapted from (Jackson-Lewis et al. 2015) 
 
 
1.4 Translocator protein 18 (TSPO) 
1.4.1 TSPO distribution and function  
TSPO was initially identified in 1977 as a peripheral-type benzodiazepine receptor (PBR), 
which is a binding site for benzodiazepines outside the CNS whose tissue distribution, 
function and subcellular localization differ from the CNS benzodiazepine receptors (Braestrup 
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and Squires 1977). Subsequently, it was reported that TSPO is localized in the outer 
mitochondrial membrane and is assumed to play a crucial role in the transfer of cholesterol 
from the outer to the inner mitochondrial membrane (Papadopoulos et al. 1997; Rupprecht et 
al. 2009). The HUGO Gene Nomenclature Committee redesignated this protein as TSPO in 
2006, reflecting its putative function in steroid translocation (Papadopoulos et al. 2006).  
TSPO is widely expressed in many organs, including kidney, heart, spleen, lung and brain etc. 
(Gavish et al. 1999). It is especially abundant in steroid synthesizing cells, such as cells in the 
adrenal and gonadal tissue (Lacapere and Papadopoulos 2003; Papadopoulos et al. 2006). 
TSPO was initially reported to be only expressed in microglia (Casellas et al. 2002) and 
astrocytes (Maeda et al. 2007) in the brain. However, several other studies also showed TSPO 
expression in neuronal cells, including olfactory bulb neurons (Wadsworth et al. 2012), 
neuroblastoma and glioblastoma cell lines (Decaudin et al. 2002), cerebellar granule cells 
(Varga et al. 2009), and rat dorsal root ganglia sensory neurons (Karchewski et al. 2004). 
1.4.1.1 Role in cholesterol transport 
One of the best-characterized functions of TSPO is its high-affinity binding to cholesterol and 
its transportation from the outer to the inner mitochondrial membrane in steroidogenic cells, 
which is the rate-limiting step for steroid synthesis (Papadopoulos et al. 2006; Papadopoulos 
et al. 2007). After entering mitochondria, cholesterol is then converted to pregnenolone via a 
side chain oxidative cleavage by cytochrome P450SCC, which is the precursor of all other 
neurosteroids (Rone et al. 2009; Jaipuria et al. 2017). It has been shown that TSPO knockout 
mice display abnormalities in steroidogenesis in an age-dependent manner (Barron et al. 
2018). Thus TSPO is thought to be essential for neurosteroids production. However, some 
other studies showed conflicting results. For example, Banati and colleagues reported that the 
cholesterol and pregnenolone biosynthesis was not affected in global TSPO knockout mice 
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(Banati et al. 2014). Another recent study also showed that the steroidogenesis was not 
affected in CRISPR/Cas9‒TSPO knockout mice (Tu et al. 2014). 
1.4.1.2 Other functions of TSPO 
TSPO has been reported to be associated with a wide range of cellular functions, e.g., 
mitochondrial permeability transition pore (mPTP) formation, regulation of mitochondrial 
reactive oxygen species (ROS) levels, cell proliferation and neuroinflammation (Chen and 
Guilarte 2008; Cosenza‐Nashat et al. 2009; Scarf et al. 2009).  
Recently, a study demonstrated that mitochondrial homeostasis and mitochondrial 
permeability transition pore (mPTP) were affected in TSPO knockout fibroblasts (Tu et al. 
2016). Also, an increased mitochondrial fatty acid oxidation and a decreased oxygen 
consumption rate (OCR) were observed in steroidogenic cells or microglia in TSPO knockout 
mice (Banati et al. 2014; Zhao et al. 2016a). However, the underlying molecular mechanisms 
are still unclear and require further investigation. 
1.4.2 TSPO structure 
TSPO is an evolutionarily conserved ubiquitous 169-amino-acid protein with five 
transmembrane helices (Fan et al. 2012; Li et al. 2015; Guo et al. 2015). In 2014, the high-
resolution structure of recombinant mouse TSPO was determined by using NMR (Jaremko et 
al. 2014). In this study, Jaremko and colleagues deciphered the 3D structure of the mTSPO, in 
complex with its synthetic ligand PK11195, in dodecylphosphocholine (DPC) micelles as 
shown in Figure 1.3. There, the five transmembrane helices of Emapunil were presented in the 
clockwise order (TM1-TM2-TM5-TM4-TM3) when viewed from the cytosol. The binding 
sites of Emapunil for cholesterol are located at the C terminus of TM5, through the 
cholesterol recognition consensus sequence (CRAC) (residues 147 to 159; Ala-Thr-Val-Leu-
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residues, which are the side chains of the TSPO structure, are essential for cholesterol 
binding. The study also revealed that the binding sites for TSPO ligands, PK11195 and 
cholesterol, are different, in accordance with previous findings that site mutations of these 
residues block the binding to cholesterol but not to PK11195 (Delavoie et al. 2003). The 
authors further suggested that monomeric TSPO binds to cholesterol in nanomolar affinity, 
and that cholesterol binding might modulate the oligomerization of TSPO. 
 
 
Figure 1.3 High-resolution of the mTSPO-PK11195 complex  
(A) NMR spectroscopy views of the 20 lowest-energy structures for backbone ribbons (silver, upper 
panel) and atoms (blue, lower panel), the ligand (black) and membrane boundaries (gray dotted 
lines); (B) Cylindrical view of the lowest-energy structure represented in spheres; (C) Cytosolic view 




Another two recent publications elucidated the crystal structures of bacterial TSPOs by X-ray, 
with more emphasis on the structural changes caused by the A147T polymorphism (Li et al. 
2015; Guo et al. 2015), as individuals with TSPO A147T polymorphism show lower binding 
affinity to most TSPO PET ligands (Costa et al. 2009). Both studies indicate that the A147T 
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polymorphism results in tilts and twists between TM1 and TM2 helices with the sterical 
hindrance of ligands binding by the alanine side chain.  
1.4.3 TSPO ligands 
1.4.3.1 Endogenous ligands of TSPO 
Many endogenous ligands of TSPO were identified over past decades, such as cholesterol, 
tetrapyrroles which including (protoporphyrin IX (PPIX), mesoporphyrin IX, 
deuteroporphyrin IX) and Diazepam Binding Inhibitor (DBI) with its post-translational 
products (Bovolin et al. 1990) (Wendler et al. 2003; Li et al. 2013; Vanhee et al. 2011). The 
most famous endogenous ligand is cholesterol which shows nanomolar binding affinity to 
TSPO, and its binding site located at a conserved CrAC domain in the C-terminus of TSPO 
(Li et al. 2001b; Jaremko et al. 2014). Porphyrins (cyclic tetrapyrroles with prominent 
physiological functions) are another class of endogenous TSPO ligands which were reported 
in 1987 for the first time (Verma et al. 1987; Verma and Snyder 1988). In particular, PPIX, 
which forms Heme when complexed with Fe
2⁺ ion in its center (Verma et al. 1987), is 
suggested to bind to TSPO with the highest affinity in a nanomolar range, via the same 
binding pocket as PK11195. Interestingly, once bound, TSPO can catalyze PPIX degradation 
to bilindigin, which resembles biliverdin, a blood breakdown product that functions as an 
oxyradical scavenger. Since biliverdin suppresses reactive oxygen species (ROS) production, 
it is plausible that the cleavage of PPIX by TSPO may attenuate oxidative stress, which may, 
at least, partially explain that the expression levels of TSPO are increased in activated 
microglia in response to oxidative stress and inflammation (Guo et al. 2015). This is in 
accordance with a previous report, showing increased ROS in TSPO knockouts (Frank et al. 
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2007). Altogether, these results suggest that the interaction between TSPO and PPIX plays an 
important role in heme metabolisms and inflammatory responses (Veenman et al. 2016).  
Another class of endogenous ligands is the diazepam-binding inhibitor (DBI). DBI, also 
known as acyl-CoA-binding protein for the high binding affinity to acyl-CoA esters 
(Færgeman et al. 2007) or ACbD1 (Fan et al. 2010), is widely expressed in the nervous 
system (Mocchetti and Santi 1991). DBI can stimulate mitochondrial steroid synthesis by its 
active peptide fragments, octadecaneuropeptide DbI 33–50 (ODN) and 
triakontatetraneuropeptide DbI 17-50 (TTN) (Papadopoulos et al. 1991; do Rego et al. 2007). 
Another acyl-CoA-binding domain-containing protein, named PAP7 or ACbD3, can also bind 
to TSPO, and the binding complex can mediate the transport of cholesterol into mitochondria 
in steroidogenic cells (Fan et al. 2010; Li et al. 2001a; Liu et al. 2006). These studies suggest 
that acyl-CoA-binding proteins or acyl-CoA itself could bind to TSPO and further regulate 
cholesterol transport. 
Endozepines are a family of neuropeptides derived from DBI by endogenous proteolysis, 
which are widely used for prolonged sedation in intensive care units (ICUs) (Martin et al. 
2006). The sedative and hypnotic effects are mediated by their binding to GABAA (γ-
aminobutyric acid type A) receptor (Costa and Guidotti 1991; Sigel and Steinmann 2012). 
Endozepines can bind to TPSO with multiple binding sites, and they need other partner 
proteins such as VDAC for maximal binding (Sigel and Steinmann 2012). In the CNS, 
endozepines are primarily expressed in glial cells and involved in immune response where 
they exhibit anti-inflammatory effects (Kim et al. 2006). Also, CSF endozepines levels are 
higher in AD patients than in age-matched healthy controls (Ferrarese et al. 1990). A recent 
study showed that the amyloid-β peptide could stimulate the synthesis of endozepines in 
astrocytes in vitro (Tokay et al. 2008). Moreover, plasma levels of endozepines are also 
increased by cecal ligation and puncture treatment, a model characterized by dysregulated 
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systemic inflammation (Clavier et al. 2014). All these reports suggest that the endogenous 
ligands of TSPO, at least in part, are involved in the inflammatory response.  
1.4.3.2 Synthetic ligands of TSPO 
In many neurodegenerative diseases, such as AD and PD, chronic neuroinflammation has 
been implicated as an important pathological contributor (McManus and Heneka 2017). 
Several studies demonstrated that the activation of microglia was often associated with 
increased TSPO expression (Wilms et al. 2003a; Karlstetter et al. 2014). Given that TSPO 
expression levels are rather low in resting microglia, it was discovered as a potential 
molecular marker for microglia associated neuroinflammation (Banati 2002). Therefore, many 
TSPO ligands were synthesized and studied both in human and mouse brain in the last fifteen 
years. 
The first generation of TSPO ligands comprises Ro5-4864 and PK-11195, which belong to 
Benzodiazepines-class and Isoquinoline Carboxamide derivatives, respectively (Le Fur et al. 
1983a; Benavides et al. 1983). Ro5-4864 was classified as an agonist while PK11195 as an 
antagonist, based on their opposite effects on neuronal seizures rates (Le Fur et al. 1983b; 
Benavides et al. 1984). PK11195 is so far the best characterized radiotracer of TSPO which is 
widely used as a reference ligand to compare other newer ligands. It is important to note that 
binding affinity and selectivity to TSPO is significantly different between TSPO ligands, for 
example, PK11195 is limited in clinical application, mostly due to its high non-specific 
binding to plasma protein (highly lipophilic), as well as low brain permeability (Vivash and 
O’Brien 2016). 




Figure 1.4 Structures of several representative TSPO ligands. 
Figure is adapted from (Alam et al. 2017) 
 
 
To improve the signal-to-noise ratio, scientists developed many second and third generation 
ligands from derivatives of the classical ligands and also from other structural classes (Figure 
1.4). The new classes of ligands include acetamides (derivatives with the diazepine ring 
opening from Ro5-4864, e.g., DAA1106, FEDAA1106 and PBR28), Vinyl alkaloids (e.g., 
vinpocetine), Aryl-oxodihydropurines (e.g., Emapunil and DAC), Pyrazolopyrimidine (e.g., 
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DPA-713 and DPA-714) and Imidazopyridineacetamides (e.g., CLINME, CB148, CB251 and 
PBR111) (Alam et al. 2017).  
All these newly developed ligands showed lower lipophilicity and higher selective affinity to 
TSPO compared with PK11195. However, most of them still showed non-specific binding to 
other proteins (Vivash and O’Brien 2016).  
Similar to PK11195, these novel ligands with higher specificity exhibit different binding 
affinities to TSPO due to single nucleotide polymorphism (SNP). The polymorphism (rs6971) 
of TSPO gene (A147T), which was first identified in 2012 using unlabeled PBR28 (Owen et 
al. 2011) and was further confirmed by another independent study using [
18
F]PBR111 (Guo et 
al. 2013), brings three allele combinations with different binding affinity: AA with the highest 
affinity, AT with mixed affinity while TT with lowest affinity (Owen et al. 2012; Dickstein et 
al. 2011). These different binding affinities need to be considered when testing novel ligands.  
1.4.4 TSPO radiotracers applied in PD 
Most of the TSPO ligands were primarily developed for positron emission tomography (PET) 
or Single photon emission computed tomography (SPECT) imaging studies. They provide a 
valuable tool for tracking and quantification of inflammation in vivo, e.g., in brain tumors, 
neurodegenerative diseases and psychiatric disorders. For example, in 6-OHDA-lesioned 
rodent model of PD, [
11
C]-(R)-PK11195 binding was increased in the substantia nigra and 
striatum (Bartels and Leenders 2007), which was in line with more widespread activated 
microglia as assessed by CD68 immunofluorescence staining (Cicchetti et al. 2002) and by 
other studies in the MPTP mouse model (Belloli et al. 2017; Roussakis and Piccini 2018). PD 
patients also showed increased [
11
C]-(R)-PK11195 retention in the thalamus, striatum, frontal 
and cingulate cortex compared with healthy controls (Gerhard et al. 2004; Gerhard et al. 
2006). Furthermore, a recent study showed increased striatal [
11
C]-(R)-PK11195 binding in 
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patients in very early PD stages (mean UPDRS motor score 7.2) (Iannaccone et al. 2013). It is 
important to note that 
18
F have longer half-life compared with 
11
C, so the novel ligands with 
18
F become more widely used for clinical studies (Schweitzer et al. 2010). The recent study 
using the second generation ligand [
18
F]-FEPPA yet showed no significant increase of TSPO 
tracer retention in PD patients (Koshimori et al. 2015). This may partially be due to the 
different ligands and patient populations. Interestingly, in several longitudinal studies in PD 
patients, the retention of TSPO ligands had no significant changes during 4 weeks or 24 
months, which indicates that microglia may be activated at an early stage of PD and then 
remained stable during pathological progression (Ouchi et al. 2005; Gerhard et al. 2006).  
1.4.5 TSPO ligands have therapeutic effects in neurodegenerative 
diseases  
Although most of ligands were developed primarily for PET imaging study, some TSPO 
ligands were found to have neuroprotective and anti-inflammatory effects (Papadopoulos and 
Lecanu 2009) and TSPO was suggested to be a promising therapeutic target in 
neurodegenerative diseases (Papadopoulos and Lecanu 2009; Rupprecht et al. 2010; Da Pozzo 
et al. 2015). For example, the TSPO ligand RO5-4864 could effectively attenuate the 
neuropathology and behavioral impairment in an AD mouse model (Barron et al. 2013). It has 
also been reported in several studies that the TSPO ligands modulate microgliosis and show 
protective effects in retinal degeneration (Scholz et al. 2015; Rashid et al. 2018b), MS (Leva 
et al. 2017), traumatic brain injury (Papadopoulos and Lecanu 2009), and depression (Gavioli 
et al. 2003). 
It is essential to note that some TSPO ligands can bind to other proteins, apart from binding to 
TSPO. For example, the synthetic TSPO ligand Etifoxine is a clinically approved drug for 
anxiety disorder outside Europe and the US. The anxiolytic effects of Etifoxine were caused 
  Introduction 
34 
 
by directly binding and activating GABAA receptor complex, and by stimulating TSPO-
mediated neurosteroids production.  
However, another TSPO agonist in aryl-oxodihydropurines class, Emapunil (=AC-5216 or 
XBD-173, as shown in Figure 1.4), shows nanomolar binding affinity to the mitochondrial 
purified TSPO (i.e., IC50 = 3.04 nM or 2.73 nM for TSPO purified from rat or human glioma 
cells, respectively). It also shows negligible affinity to a total of 90 other transporters, ion 
channels and receptors, which include GABAA receptors (Kita et al. 2004; Rupprecht et al. 
2009; Ravikumar et al. 2016). Emapunil has been intensively studied over the past few years 
and showed neuroprotective and anti-inflammatory effects in MS (Leva et al. 2017) and 
depression models (Gavioli et al. 2003). It also exerts rapid anxiolytic effects with no sedation 
and withdrawal symptoms in the CCK4 challenged human volunteers, with enhanced 
GABAergic neurotransmission (Rupprecht et al. 2009; Kita et al. 2009). Most importantly, 
Emapunil has already been tested for safety and tolerability in a phase II clinical trial in 
patients with generalized anxiety disorder (Rupprecht et al. 2010), although it failed to reach 
positive clinical outcome criteria, partially due to single nucleotide polymorphism (SNP) 
carriers (Owen et al. 2011; Owen et al. 2012). Given the high affinity and selectivity to TSPO, 
Emapunil is in a top position for drug development to treat neurodegenerative diseases.  
Although the precise molecular and cellular mechanisms of the neuroprotective effects 
mediated by TSPO ligands in neuropathological conditions are not well defined, stimulation 
of mitochondrial steroid synthesis and suppression of ROS product in activated microglia 
have been widely discussed as possible mechanisms (Wang et al. 2014; Guo et al. 2015). 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and consumables 
In this study, Emapunil was kindly provided by Andrea Leonov and Prof. Dr. Markus 
Zwechstetter. It was prepared as previously reported (Maeda et al. 2007), as shown in Figure 
2.1. All the other chemicals were purchased either from AppliChem GmbH (Germany), 
Merck group (Germany) or Sigma-Aldrich GmbH (USA). Plastic consumables were 
purchased from Thermo Fisher Scientific (USA), Eppendorf AG (Germany) and BD Falcon™ 
(France) unless indicated otherwise. 
 
Figure 2.1 Emapunil preparation diagram 
Reaction reagents and conditions depicted in the diagram: (a) NaOEt with EtOH at 0-80°C for 4 h, 81%; 
(b) POCl3 at 90°C for 4 h, 99%; (c) glycine, Et3N and EtOH at 78°C for 4 h, 100%; (d) N-
ethylbenzylamine, PyBOP, Et3N and DMF at 22°C for 2 h, 100%; (e) NaOH, EtOH and water at 78°C for 
2 h, 82%, (f) diphenyl phosphorazidate, Et3N and DMF at 100°C for 6 h, 55%, (g) MeI, NaH and DMF, at 
22°C for 3 h, 78%. 
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2.1.2 Buffer solutions 
Buffer solutions used in this study were prepared as shown in Table 2.1 
Table 2.1 preparation of buffer solutions used in this study 
Buffer formula concentration Notes 

















pH = 7.4 
Tissue homogenization 
buffer for MPTP and 
dopamine metabolites 
measurement 
perchloric acid 0.1 M  
HPLC mobile phase 
buffer 
sodium phosphate 












70ml to 60°C 
2-3 
10 ml 
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2.1.3 Commercial reagents, compounds and consumables 
The commercial reagents and plastic Consumables are listed in Table 2.2. 
Table 2.2 Overview of commercial reagents, compounds, and consumables 
Commercial reagents, compounds and 
consumables 
Catalog number company 
Nunc™ EasYFlask™ Cell Culture Flasks 10364131 Thermo Scientific™ 
Nunc™ Cell-Culture Treated Multidishes 10469282 Thermo Scientific™ 
Poly-L-ornithine P3655-50MG Sigma-Aldrich 
Fibronectin F1141-2MG Sigma-Aldrich 
DMEM/F12 medium D8062-6X500ML Sigma-Aldrich 
N2 supplement 17502048 LIFE Technologies 
bFGF 233-FB-025 R und D Systems 
db-cAMP D0627-250MG Sigma-Aldrich 
Tetracycline T7660-5G Sigma-Aldrich 
GDNF 212-GD-010 R und D Systems 
0.05 % Trypsin-EDTA 25300054 LifeTechnologies 
Fetal bovine serum 10309433 Fisher Scientific 
Cell culture grade DMSO A3672,0250 AppliChem 
MPTP M0896 Sigma-Aldrich 
Rotenone 45656-250MG Sigma-Aldrich 
toyocamycin Cay17371-5 Biomol 
Emapunil SML1223-5MG Sigma-Aldrich 
MPP
+
 D048 Sigma-Aldrich 
Tissue-Tek
®
 O.C.T. 4583 SAKURA 
Lipofectamine
®
 RNAiMAX Reagent 13778150 LIFE Technologies 
Amersham
™
 ECL Prime Western Blotting 
Detection Reagent 
GERPN2232 




 Protease inhibitor cocktail 000Z00011697498001 Roche Diagnostics 
ESIRNA HUMAN TSPO EHU080541-20UG Sigma-Aldrich 





 siRNA Negative Control SIC003 Sigma-Aldrich 
Negative Control siRNA 1027310 Qiagen 
DPX 06522 Sigma-Aldrich 
2.1.4 Cell culture medium  
Lund human mesencephalic (LUHMES) cells were used in this study for in vitro experiments. 
Two different cell culture media (proliferation and differentiation medium) are listed in Table 
2.3 and Table 2.4. Proliferation and differentiation medium can be stored at 4°C for 2 weeks 
and need to be filtered before use. 
2.1.4.1 Proliferation medium components 
Table 2.3 Overview of proliferation medium components 
Components volume 
DMEM/F12 medium 495 mL 
N2 supplement 5 mL 
bFGF stock solution (25 µg/mL) 800 µL 
2.1.4.2 Differentiation medium components 
Table 2.4 Overview of differentiation medium components 
components volume 
DMEM/F12 medium 490 mL 
N2 supplement 5 mL 
db-cAMP stock solution (49 mg/mL) 5 mL 
tetracycline stock solution (1 mg/mL) 500 µL 
GDNF stock solution (5 µg/mL) 200 µL 
2.1.5 Commercial kits 
Commercial kits used in this study are listed in Table 2.5.  
Table 2.5 Overview of commercial kits 
















 ABC HRP Kit PK-6200 
Vector 
Laboratories 





 bioassay kit LT17-217 Lonza Verviers 
RNeasy
®
 Mini Kit 74104 Qiagen 





Green PCR Master Mix 4367659 
LIFE 
Technologies 
2.1.6 Primers  
All primers in this study were ordered either from AGCT core facility (Max-Planck Institute 
of Experimental Medicine, Göttingen, Germany) or from Sigma Aldrich (Munich, Germany) 
with 50 mM concentration, the working concentrations were diluted to 10 mM or 20 mM, the 
stock and working solutions were stored at -20°C. The primers are listed in Table 2.6. 
Table 2.6 Overview of the primers for qPCR used in this study 
Gene (protein) Forward Primer Reverse Primer 





Fizz2 (FIZZ2) TGGAGAATAAGGTCAAGGAAC GTCAACGAGTAAGCACAGG 






Arg1 (Arg1) GGAAGACAGCAGAGGAGGTG TATGGTTACCCTCCCGTTGA 
Iba1 (IBA1) GTCCTTGAAGCGAATGCTGG CATTCTCAAGATGGCAGATC 








IP10 (IP10) TGAGCAGAGATGTCTGAATCCG TGTCCATCCATCGCAGCA 














































GAPDH human GAAGGTGAAGGTCGGAGT CATGGGTGGAATCATAATGGAA 
2.1.7 Antibodies 
The primary and secondary antibodies are listed in Table 2.7 and Table 2.8, respectively.  
Table 2.7 Overview of the primary antibodies  
 










anti-rabbit IgG donkey biotinylated 1:200 (IHC) RPN-1004 GE Healthcare 
anti-Rabbit IgG Donkey 
Alexa Fluor 
488 






1:1000 (IHC) A-21450 
Thermo fisher 
scientific 
anti-Rabbit IgG Goat Alexa Fluor 1:1000 (IHC) A11008 Thermo fisher 






TH rabbit polyclonal 1:1000 (IHC) AB152 Millipore 
IBA rabbit polyclonal 1:2000 (IHC) 019-19741 WAKO 
GFAP Guinea pig polyclonal 1:1000 (IHC) 173004 
Synaptic 
Systems 
TSPO rabbit polyclonal 1:500 (IHC) ab109497 Abcam 
TH chicken 1:1000 (IHC) ab76442 Abcam 






Goat Cy3 1:500 (IHC) ab97145 Abcam 
Anti-Rabbit IgG Goat HRP 1:1000 111-035-003 Dianova 
2.1.8 Software 
The software used in this study is listed in Table 2.9.  
Table 2.9 Overview of software used in this study 
Software Application Source 
GraphPad Prism 7 Statistical and figure analysis GraphPad Software Inc. 





qPCR data analysis Thermo Fisher Scientific 
Adobe Illustrator CS5.1 Figure design Adobe System Inc. 
MS Office Excel 2010 Data analysis Microsoft 
EndNote x7 references management Clarivate Analytics 
MS Office Word 2010 Text processing Microsoft 
Zen Blue 2.3 lite Image acquisition and processing Zeiss 
Fiji/ImageJ Image analysis http://fiji.sc/Fiji 
 
2.2 Methods 
2.2.1 The experimental schedule 
In this experiment, a total number of 75 C57BL/6JRj female mice were purchased from 
Janvier Labs, France. They were 8-week-old when the experiment started. They were housed 
in groups of five in individually ventilated cages in an air-conditioned room and kept under a 
12-h light-dark cycle with free access to standard food and water. All animal experiments 
were carried out under the German animal protection law and legislation of the State of Lower 
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Saxony. All protocols had been reviewed and approved before experiments by animal welfare 
board (Landesamt für Verbraucherschutz, Braunschweig, Lower Saxony, Germany, reference 
number 12/2210). Two mice were sacrificed during the treatment because of severe injuries. 
2.2.1.1 Subacute MPTP treatment  
Mice were randomly divided into 3 groups with 25 mice per group. Two groups of mice 
received i.p. injection of 30 mg/kg body weight MPTP (free base from Sigma, dissolved in 
0.9% saline) every 24 h for 5 consecutive days. Another group of mice received i.p. injection 
of saline with the same schedule as saline control (Figure 3.1). 
2.2.1.2 Emapunil treatment 
From the same day of the first MPTP administration, MPTP injected mice additionally 
received i.p. injection of either DMSO or 50 mg/kg body weight Emapunil (dissolved in 
DMSO) every 48 hours for 15 days, named MPTP + DMSO group or MPTP + Emapunil 
group, individually. Saline-treated mice received i.p. injection of DMSO as control, named 
NaCl + DMSO group (Figure 3.1). 
2.2.1.3 Experimental procedure 
The experimental design is shown in Figure 3.1. Experiments started from the first injection 
of saline, MPTP, DMSO and/or Emapunil. Five mice per group were sacrificed on day 3 for 
qPCR, HPLC, and transcriptome assays. Two motor tests were conducted on day 11-13 (pole 
test) and day 14 (cylinder test), separately. On day 15, five mice per group were sacrificed for 
dopamine and its metabolites quantification. The remaining mice were perfused for IHC and 
stereological analysis.  
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2.2.2 MPTP metabolism 
On day 3, five mice per group were sacrificed 90 min after MPTP or Emapunil injection. 
Brains were immediately dissected on ice after briefly washing with PBS. The striatum was 
separated into two hemispheres and collected in cry-stock vials which were filled with 
ceramic beads at -80°C until further processing.  
For the MPTP metabolism measurement, tissue homogenization buffer was added into the 
vials containing the left striatum hemisphere at a volume of 50ul/mg tissue and then 
homogenized by Precellys 24 homogenizer. After high-speed centrifugation, supernatants 
were taken out and stored for MPP
+
 concentration measurement by HPLC. The protocol for 
HPLC measurement was adopted from (Tönges et al. 2012). 10 ul of supernatants were 
injected onto a reverse-phase column (Nucleosil 100-5 C18; Macherey-Nagel), the flow rate 
was 0.4 ml/min. The MPP
+
 signals were detected by fluorescence, the wavelengths of 
excitation and emission are 295 nm and 375 nm, respectively (Fluorescence HPLC Monitor; 
Shimadzu).  
2.2.3 RT-qPCR  
2.2.3.1 RNA extraction 
In this study, we extracted RNA from the right hemispheres of the striatum on day 3 and 
LUHMES cell lysates by using the RNeasy Mini kit according to the manufacturer’s 
instructions. The samples were disrupted and homogenized in buffer RLT with β-ME. After 5 
min incubation at RT, the samples were centrifuged at 12000g for 3 min, and supernatants 
were removed by pipetting. 70% ethanol was added into the pellet and mixed well by 
pipetting. The samples were transferred into RNeasy Mini spin columns and centrifuged at 
10000g for 30 s. Supernatants were discarded and 700 μl Buffer RW1 was added into the 
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column, centrifuged at 10000g for 30 s. This was followed by two Buffer RPE washing steps, 
and the columns were dried by another centrifuge step at 10000g for 1 min. Finally, RNA was 
eluted by adding 30–50 μl RNase-free water to the spin column membrane and centrifugation 
at 10000g for 1 min. From now on, RNA was kept on ice or at -80 ºC for storage. The quality 
and concentration of RNA were measured by NanoDrop.  







 Master Mix with ezDNase enzyme was used in this 
study for the first strand cDNA synthesis. The RNA samples were treated with ezDNase 
enzyme for DNA digestion, the reaction mixture was prepared on ice as shown in Table 2.10. 
The components were incubated at 37°C for 2 minutes after gently mixed. This was followed 
by adding 4 µL SuperScript™ IV VILO™ Master Mix and 6 μL Nuclease-free water. Next, the 
components were incubated at 25ºC for 10 min to anneal the primers and then at 50ºC for 
another 10 min to reverse transcribe RNA. After that, the enzyme was inactivated by 
incubating at 85ºC for 5 min. The cDNA was ready for qPCR amplification. 
Table 2.10 cDNA synthesis reaction mixture  
Component Volume (µL) 
10X ezDNase buffer 1 
ezDNase enzyme 1 
Template RNA (500 pg) variable 
Nuclease-free water Up to 10 
 
2.2.3.3 RT-qPCR amplification 
The qPCR amplification was conducted by using Power SYBR
®
 Green PCR Master Mix in 
StepOnePlus
™ 
Real-Time PCR system. The reaction components were prepared as listed in 
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Table 2.11. The used primers are shown in Table 2.6. The relative gene expression changes 
between target genes and the housekeeping gene (-actin) were analyzed by the 2
-ΔΔCT
 
method. The Fold-changes (FC) between groups were analyzed afterward.  
Table 2.11 RT-qPCR reaction components 
Component Volume (µl) 
2x SYBR Green Master Mix 10 
Primer-Forward (10 pmol/µl) 1 
Primer-Reverse (10 pmol/µl) 1 
Template 1 
Nuclease-free water up to 20 
 
2.2.4 Behavioral tests 
Pole test and cylinder test were used in this study to assess the body coordination and motor 
function.  
2.2.4.1 Pole test 
The pole test was initially introduced in 1985 by Ogawa and became a useful tool for 
evaluating the motor dysfunction caused by striatal dopamine depletion in mouse PD models 
(Ogawa et al. 1985). A rough-surfaced pole (diameter 12 mm; height 55 cm) was vertically 
placed in the home cage of the tested mouse, and the mouse was placed on the top of the pole 
with head-upward. Two parameters were recorded during the test: the time until the mouse 
orients the head downward, and the time until the mouse descend along the pole to touch the 
ground with the forelimbs. In this study, mice were trained from day 11 after the initial 
injection for 2 consecutive days, which include three trials per day with a 10 min interval for 
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mice to recovery. On day 13, mice performed five consecutive trials with 10 min intervals and 
the entire procedure was recorded. Time values were calculated and averaged from five 
consecutive trials. No mice flipped or fell down in this study. 
2.2.4.2 Cylinder test 
The cylinder test was initially described by Schallert in 2000 for assessing the independent 
use of forelimbs in unilaterally lesioned mouse models, but it has also been widely used for 
measuring forelimb akinesia and whole body coordination (Schallert and Tillerson 2000). 
In this study, the cylinder test was conducted following the pole test on day 14. The individual 
mouse was placed in a transparent cylinder (diameter: 11.5 cm; height: 25 cm) for 5 min and 
all movements were video recorded. The mice had never been habituated to the cylinder 
before and were free to explore. The number of rearing was counted. A mirror was placed 
behind the cylinder to make sure that all forelimb movements were recorded when mice 
turned away from the camera. The rearing activities were normally counted up to thirty times 
per mouse. The usage of forelimbs against the wall for support after rearing was classified 
according to the following asymmetry criteria: (i) simultaneous co-using of both left and right 
forelimbs for contacting the cylinder wall or lateral stepping movements with alternatively 
using of both left and right forelimbs along the wall, was recorded as ‘both’ forelimbs rearing; 
(ii) full rearing of the entire body without touching the wall was recorded as ‘free’ rearing; 
(iii) the first forelimb used to contact the wall for support after full rearing was recorded for 
that limb, such as either ‘left’ forelimb rearing or ‘right’ forelimb rearing. In addition, mice 
with too little tendency for exploration (<5 rearings) or too much (jumping over) during a test 
session were not included in this study. The percentages of ‘both’, ‘right’, ‘left’ or ‘free’ 
forelimbs rearing within the entire observation time were then subtracted and calculated. 
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2.2.5 Neurochemical analysis of dopamine and dopamine metabolites 
At day 15, all mice were sacrificed. Brains were either freshly prepared for neurochemical 
analysis of dopamine and metabolites or perfused for histology assays. 
In order to analyze the functional impairment of the dopaminergic terminals in the striatum 
after treatment, five mice per experimental group were sacrificed by cervical dislocation at 
day 15, and brains were removed immediately after sacrifice. After briefly rinsing with PBS, 
the left hemispheres of the striatum were dissected on ice and stored into cryo stock vials with 
ceramic beads at -80°C until further processing. The tissues were then homogenized by 
Precellys-24 homogenizer, followed by centrifugation at 5000 g for 1 min. Supernatant was 
transferred into a new vial and again centrifuged at 10000 g for 30 min at 4°C. 50 μl of the 
supernatant was transferred into an HPLC vial for dopamine, homovanillic acid (HVA) and 
DOPAC measurement.  
The HPLC system contains a C18 reverse-phase HR-80 catecholamine HPLC column (ESA), 
a Guard cell kept at 600 mV to oxidize impurities in the eluent, and an ESA Coulochem II 
electrochemical detector equipped with a 5011A analytic model detector (E1 = 50 mV, E2 = 
400 mV). The samples were injected into columns (ESA) with a flow rate of 0.4 ml/min 
mobile phase (filtered and degassed), to prevent pH changing during the mobile phase. Data 
were analyzed with Chromeleon Chromatography Data System (Dionex) and displayed as 
ng/mg wet tissue.  
2.2.6 Histology  
2.2.6.1 Transcardial Perfusion and tissue cryo-section 
At day 15, another cohort of 8-10 mice per experimental group was deeply anesthetized by 
intraperitoneal injection with 14% chloral hydrate. The whole body including the brain was 
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perfused with cold PBS and 4% PFA using MPII mini peristaltic pump (flow rate: 3 ml/min). 
After fixation, brains were removed, post-fixed in 4% PFA overnight and transferred into 
30% sucrose for cryopreservation for 48 h at 4°C. After that, brains were snap frozen on dry 
ice with the protection of Tissue-Tek O.C.T. (Sakura) and stored at -80°C until further 
processing.  
For immunohistochemistry, brains were cryosectioned into 30 μm coronal free-floating 
sections using a cryostat (CM1900, Leica, Germany), which were stored in 48 well plates 
containing TBS with 0.1% NaN3 at 4°C until further use. 
2.2.6.2 Immunohistochemistry  
For quantifying TH- and Nissl- positive neurons in the substantia nigra by stereology, every 
fifth section in the substantia nigra was stained using the free-floating method. Sections were 
washed 3 times with 1x TBS for 5 min each to wash the 0.1% NaN3 away, and the 
endogenous peroxidases were quenched by 40% methanol and 1% H2O2 in TBS for 15 min. 
After washing, the sections were blocked with 3% BSA and 0.5% Triton x-100 in TBS 
(TBST) for 1 h at room temperature. Next, sections were incubated with anti-TH antibody 
(Table 2.7) in blocking solution for 48 h at 4°C and biotinylated donkey anti-rabbit IgG 
(Table 2.8) for 2 h at room temperature. This was followed by incubation with 
VECTASTAIN ABC peroxidase standard kit for 2 h at room temperature. Visualization was 
performed by using chromogen DAB (DAB peroxidase substrate Kit) for 2 to 5 min at room 
temperature depending on the color change. The reaction was stopped by washing with TBS 3 
times, and the sections were mounted on SuperFrost Plus microscope slides. The slides need 
to be dried at room temperature for 2 days. After rehydration, Nissl staining was 
counterstained using 0.5% Cresyl violet at room temperature for 2 to 10 min. This was 
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followed by dehydration with an ascending concentration series of ethanol and xylene. In the 
end, slides were mounted with DPX. 
2.2.6.3 Stereological quantification of substantia nigra neurons  
After drying overnight, the DAB and Nissl stained slides were used for stereological 
quantification of TH- and Nissl- positive neurons, using Stereo Investigator software. Slides 
were fixed under a Zeiss Axioplan microscope equipped with a computer-controlled 
motorized stage (Ludl Electronics, Hawthorne, USA). The substantia nigra region was 
outlined at 2.5x objective magnification with the optical fractionator method. The number of 
positive neurons was counted at 100x objective magnification with following criteria: 150x 
150 μm grid layout, 50 x 50 μm counting frame, 15 μm dissector height and 3 μm guard. The 
counting was performed blinded. 
2.2.6.4 Immunofluorescence  
Immunofluorescence was conducted for quantification of the microgliosis, astrogliosis and 
identification of TSPO expression in TH positive neurons.  
Every tenth section through the striatum (3 slices/brain) was washed with 1x TBS to remove 
the 1%NaN3, and antigen retrieval was performed using citrate buffer for 30 min at 95°C. 
Sections were still kept in the antigen retrieve buffer for 30 min after moved out from the 
water bath. Once cooled to room temperature, sections were rinsed with 1x TBS and blocked 
with 3% BSA in 0.5% TBST for 1 h at room temperature. This was followed by primary 
antibodies (Table 2.7) incubation for 48 h at 4°C in blocking solution, On the third day, 
sections were incubated with the corresponding secondary antibodies (Table 2.8) for 2 h at 
room temperature. DAPI counter-staining was then performed for 10 min at room 
temperature. Sections were then washed with TBS and mounted with Mowiol 4-88. 
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2.2.6.5 Quantification of microglia activation and astrogliosis 
For quantifying microglia activation and astrogliosis, every tenth section through the striatum 
from each brain (3 slices/brain) was stained with Iba1 and GFAP. The sections were tile 
scanned and automatically stitched using Zeiss Axio Observer. Z1 microscope connected to 
Apotome.2 at 20x objective magnification. The number of Iba1 or GFAP positive cells and 
the counting area in the striatum were counted using Fiji-ImageJ with a cell counter analysis 
plug-in, and the result was presented as positive cells normalized to the analyzed area. 
2.2.6.6 Identification of TSPO expression in TH+ neurons 
To identify the co-localization of TSPO and TH staining, 1 slice containing the substantia 
nigra from each brain was co-stained with antibodies against TSPO and TH. Fluorescent 
images were taken using an LSM 700 Zeiss laser scanning confocal microscope under 63x 
objective magnification, with 16-bit and 1024 x 1024 pixels.  
2.2.7 RNA-Seq and bioinformatical analysis 
2.2.7.1  Tissue dissection and RNA isolation  
For transcriptome assay, another cohort of 8-week-old female C57BL/ 6J Rj mice was 
purchased from Janvier Lab. They were randomly divided into 3 groups and received the 
same treatment as previously described. On day 3, 8 mice from each experimental group were 
sacrificed by cervical dislocation 90 min after the i.p. injection. Brains were quickly isolated 
on ice and dissected into regions. The striatum tissue was snap-frozen in liquid nitrogen and 
stored at -80°C. For RNA extraction, tissue was homogenized in TriReagent (Sigma), and 
RNA was extracted according to the manufacturer’s instruction. The extracted RNA was 
further treated with 2U of DNaseI (Invitrogen) for 20 min at 37°C and re-purified with 
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Phenol/Chloroform. The purified RNA was resuspended in DEPC water and stored at -80°C 
until further processing. 
2.2.7.2 RNA sequencing 
The quality of RNA was measured using Agilent 2100 Bioanalyzer (Agilent Technologies) 
and Qubit (Life Technologies). RNA library and mRNA sequencing cluster were generated 
using Illumina HiSeq 2000 according to Illumina standard protocols (TruSeq, Illumina). The 
Library was mapped to the reference genome (mm10, STAR aligner) with the following 
parameters:-outFilterMismatchNmax2-outSAMstrandField intronMotif-sjdbOverhang 49. 
The Counts were generated using htseq (Anders et al. 2015).  
2.2.7.3 Bioinformatical analysis 
To reveal Gene Ontology (GO) biological processes, molecular functions and localizations 
between the differentially expressed genes in saline control, MPTP + DMSO mice and MPTP 
+ Emapunil mice, the differentially expressed genes between groups were queried using 
DESeq2 (Love et al. 2014). The threshold for clarifying the differentially expressed genes is: 
log2FC > |0.2| and adjusted p-value (Benjamini-Hochberg) < 0.05. Overlaps of the 
differentially expressed genes were calculated using Venny (Oliveros 2007-2015). 
Gene Ontology (GO) functional enrichment analysis was carried out using Webgestalt 2.0 
(http://www.webgestalt.org/option.php/, (Kirov et al. 2014; Wang et al. 2013; Zhang et al. 
2005a). Gene network pathways analysis (p-value < 0.1) was conducted using Cytoscape 
3.0’s plugin ClueGO (Bindea et al. 2009). Transcription factor binding site enrichment 
analysis was performed with PSCAN using the TRANSFAC database (Zambelli et al. 2009). 
R was utilized for tracing Heatmaps and individual genes (Team 2008). 
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2.2.8 LUHMES cell culture experiments 
All cell culture work was conducted under the S1 security level. The work was carried out 
entirely under sterile conditions, including 70% ethanol antiseptic cleaning of all equipment, 
UV- light treatment and sterile filtration of all media and solutions with a 0.22 μm 
polyethersulfone filter. 
2.2.8.1 Coating of cell culture flasks and dishes 
The stock solution of PLO was prepared with ddH2O to a concentration of 5 mg/mL. The 
working solution was then diluted 1:100 with ddH2O from the stock solution to the final 
concentration of 0.05 mg/mL. The working solution of Fibronectin was diluted 1:200 from the 
stock solution (1 mg/mL) with ddH2O to the final concentration of 5 µg/mL. The working 
solution was filtered before use. 
The surfaces of multi-well plates, dishes or flasks were coated for LUHMES cells attachment. 
In the proliferation phase, it is sufficient to coat with PLO only. However, a double coating 
with PLO and Fibronectin in a row is necessary to allow the outgrowth of cell processes in the 
differentiation phase. The coating procedure needs to be at least 6 h at 37°C or overnight at 
room temperature/4°C. The coating solution was added in sufficient volume to cover the 
surface (see Table 2.12) and rinsed three times with sterile PBS after coating. All residues 
were removed and air dried before use. 
Table 2.12 Minimal volume of PLO and fibronectin for different well sizes  
Multi-well plates Size of well (cm
2
) PLO, fibronectin (µl) 
6 9.6 1750 
6 cm dish 28 5000 
75 cm
2
 flask 75 12000 
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2.2.8.2 Maintenance and differentiation  
LUHMES cells is an immortalized human dopaminergic neuronal precursor cell line (Szegő 
et al. 2017; Scholz et al. 2011). In this experiment, LUHMES cells were first grown and 
expanded with proliferation medium in pre-coated flasks (see section: Proliferation medium 
components). The proliferation medium was changed every 2
nd
 day. To conduct experiments, 
the proper amount of LUHMES cells (at a density of 150,000 cells per cm
2
) were transferred 
to 6-well plates with differentiation medium (see section: Differentiation medium 
components). 50% of the differentiation medium was changed on the second day after 
differentiation. From then on, the medium was kept without further changes for six more 
days.  
2.2.8.3 siRNA transfection 
To down-regulate the expression level of TSPO via siRNA, LUHMES cells were transfected 
with the esiRNA EHU080541 using Lipofectamine RNAiMAX transfection reagent four days 
after differentiation. Negative control siRNA from Qiagen was used as control. 
The siRNA mixture 1 and 2 were prepared separately, as shown in Table 2.1, and were gently 
mixed by pipetting. Mixtures were incubated for 5 min at room temperature and then equally 
distributed into the cell culture medium. 
Table 2.13 Scheme for preparing siRNA mixture 1 and 2 
Component 6-well plates (each well) Notes 













 Medium 150 μL 
Mixture 2 
siRNA (10 μM) 3 μL 
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2.2.8.4 Toxicity assay 
In the toxicity assay experiments, LUHMES cells were transfected with either TSPO or 
control siRNA at day 4 after differentiation. At day 7, cells were treated with either Emapunil 
(5 μM) or DMSO as control at day 7 after differentiation. 12 h later, LUHMES cells were 
treated with either DMSO, MPP
+
 (10 μM in DMSO) or rotenone (10 μM in DMSO). After 24 
h incubation, supernatants were harvested for toxicity measurements using ToxiLight assay. 
In brief, 50 μl of reagent were added to 50 μl of culture supernatants, the pure medium 
without cells was treated as blank control, after incubation at room temperature for 5 min, 
luminescence was measured using FLUOstar Omega (BMG labtech, Germany). 
2.2.8.5 RT-qPCR assay for Xbp1 and XBP1s analysis 
For mRNA isolation and qPCR, LUHMES cells were also transfected with either TSPO or 
control siRNA at day 4 after differentiation. At day 7, LHUMES were treated for 12 h with 
either DMSO, toyocamycin (Sigma, 1 μM in DMSO), Emapunil (5 μM) or toyocamycin plus 
Emapunil. 12 h later, cells were exposed to DMSO or 10 μM rotenone. After incubating for 
another 12 h, cells were harvested for mRNA isolation, cDNA synthesis and qPCR, which 
were performed as mentioned in section: RT-qPCR. 
2.2.8.6 SDS-PAGE and Western blot analysis 
The TSPO and TH protein expression levels in LUHMES cells were quantified by Western 
blot. Cell lysates were firstly dissolved in CHAPS buffer and then centrifuged at 4500g for 10 
min. Supernatants were then denatured at 95°C for 5 min after adding sample loading buffer. 
The lysates were loaded into SDS-PAGE gel, which contains 4% stacking gel and 12% 
resolving gel as prepared in Table 2.14. 20 µg protein per sample was loaded into the gel 
pocket and separated using Bio-Rad Mini-PROTEAN
®
 Tetra electrophoresis system at 120 V 
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for approximately 120 min. The PageRuler
®
 Prestained Protein Ladder was used as the 
molecular weight reference. 
Table 2.14 Components for stacking and resolving gels for SDS-PAGE 
Component Stacking gel (4%) Resolving gel (12%) 
Acrylamide/Bis Solution 30% 4% 12% 
Tris-HCl pH 6.8 125 mM 375 mM 
SDS 0.1% 0.1% 





After electrophoresis, the proteins were transferred from the SDS gel to the Whatman
® 
nitrocellulose membrane by using the Mini-Trans Blot cell at 100V for 55 min. Next, the 
membrane was incubated with blocking solution (4 % non-fat milk powder in PBS) for 40 
min at room temperature to reduce the unspecific binding of immunoglobulins. After that, 
corresponding primary and HRP conjugated secondary antibodies were applied. Proteins were 
visualized and captured on X-Ray films (CL-XPosure
™
 Film, Thermo Fisher Scientific) by 
chemiluminescence using Pierce ECL or ECL plus substrates (Thermo Fisher Scientific) 
according to the manufacturer's protocol. TH and TSPO protein expression levels were 
quantified by the signal intensities using ImageJ and normalized to actin. 
2.2.9 Statistical Analysis 
Data were analyzed with either 2-tailed unpaired t-test (Welch’s t-test), one- or two-way 
analysis of variance followed by Tukey’s test (one-way ANOVA) or Holm Sidak test (one- or 
two-way ANOVA), as mentioned individually. The null hypothesis was rejected at the 0.05 p-
value level. Data are presented as mean ± SEM.  
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3.1 Emapunil protects from dopaminergic neuron loss in the 
subacute MPTP mouse model of Parkinsonism 
3.1.1 Experimental plan  
To better characterize the potential function of Emapunil and evaluate it as a new therapeutic 
strategy in PD, we have chosen to use an in vivo subacute MPTP mouse model, which mimics 
many aspects of the disease, including motor deficits, dopaminergic neuron loss and 
neuroinflammation. Many TSPO ligands were shown to upregulate testosterone production in 
gonadal tissue (Chung et al. 2013; Le et al. 2014; Verdile et al. 2015), and the increased 
testosterone level could be a potential risk factor for PD (Garza-Contreras et al. 2017). For 
instance, gonadectomized male mice showed dopaminergic neuron loss (Khasnavis et al. 
2013). In addition, TSPO expression differs between male and female mice (Fairweather et al. 
2014). Similar differences in TSPO expression levels were also reported in the brain of 
Drosophila (Lin et al. 2015). Therefore, we chose to study Emapunil effects only in female 
mice.  
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The 8 week-old C57BL/ 6J Rj female mice used for this study were randomly divided into 3 
groups. Two groups of mice received i.p. injections of 30 mg/kg body weight MPTP on 5 
consecutive days. These mice additionally received i.p. injections of either 50mg/kg body 
weight Emapunil (MPTP + Emapunil group) or DMSO (MPTP + DMSO group) on every 
second day, starting from the same day as the first MPTP treatment. The control group mice 
were i.p. injected with only saline and DMSO. Treatment with Emapunil or DMSO was 
continued until the mice were sacrificed at day 15 after the first MPTP dose (Figure 3.1). 
 
Figure 3.1 Schematic view of the experimental procedure. 
Top group: NaCl (black color) treated mice, middle group: MPTP (red color) and DMSO treated mice; 
bottom group: MPTP and Emapunil (green color) treated mice.  
 
3.1.2 Emapunil treatment rescues TH- and Nissl- positive neurons 
from MPTP intoxication 
We first evaluated the effects of Emapunil on MPTP induced dopaminergic neuron loss, 
which resembles the main pathological feature of PD. Tyrosine hydroxylase, which is the key 
enzyme for catalyzing the rate-limiting step in dopamine biosynthesis, is widely used as a 
marker for dopaminergic neurons in the CNS (Daubner et al. 2011). At day 15 after the first 
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MPTP injection, brain slices from 10 mice per group were processed in 
immunohistochemistry using anti-TH antibody. For each brain, we used thirteen slices among 
the substantia nigra for stereological quantification of TH- and Nissl- positive neurons (Figure 
3.2A). We found that the MPTP + DMSO group showed significantly less TH- positive 
neurons compared to control group, whereas the loss of TH- positive neurons was 
significantly prevented by additional Emapunil treatment, which indicates that Emapunil can 
prevent the MPTP induced dopaminergic neuron loss (Figure 3.2B) (NaCl group = 21572 ± 
417, n = 10; MPTP + DMSO group = 12047 ± 246, n = 10; MPTP + Emapunil group = 17547 
± 391, n = 8; one-way ANOVA with Tukey’s post hoc test; F(2,25) = 192.5, p < 0.0001; data 
are given as means ± SEM). To exclude the possibility that the protective effect of Emapunil 
was caused by up-regulation of TH expression and not by protection of neurons, we also 
quantified the number Nissl- positive neurons in the substantia nigra, which showed a 
preservation of neuron counts in the MPTP + Emapunil group compared to the MPTP + 
DMSO group (Figure 3.2C) (NaCl group = 27125 ± 352, n = 10; MPTP + DMSO group = 
20258 ± 401, n = 10; MPTP + Emapunil group = 25662 ± 423, n = 8; one-way ANOVA with 
Tukey’s post hoc test; F(2,25) = 90.46, p < 0.0001; data are given as means ± SEM).  
Since MPTP needs to be converted to MPP
+
 to exhibit toxicity after crossing the BBB, we 
further examined whether the protective effect of Emapunil was due to preventing this 
conversion from MPTP to MPP
+
. We therefore quantified the MPP
+
 levels in the striatum by 
HPLC, which showed no significant differences in the MPTP + DMSO and the MPTP + 
Emapunil group (HPLC measurements were done by Éva M. Szegő) (Figure 3.2D) (MPP
+
 
level: MPTP + DMSO group = 31.13 ± 2.837 ng/ml, n = 8; MPTP + Emapunil group = 23.14 
± 2.3 ng/ml, n = 7; 2-tailed nonparametric Mann-Whitney t-test, p = 0.0688; data are given as 
means ± SEM). Taken together, these results suggest that Emapunil protects the dopaminergic 
neurons from MPTP toxicity. 




Figure 3.2 Emapunil rescues TH- and Nissl- positive neurons. 
(A) Representative microscopy images of anti-TH antibody immunohistochemistry. Upper panel: 
NaCl group; middle panel: MPTP + DMSO group; bottom panel: MPTP + Emapunil group (scale 
bar = 200 m). Stereological quantification of the number of TH- (B) and Nissl- (C) immunoreactive 
neurons; one-way ANOVA with Tukey’s post hoc test; in between group difference P < 0.0001. (D) 
HPLC quantification of MPP
+
 levels in striatum from MPTP + DMSO and MPTP + Emapunil 
groups; 2-tailed nonparametric Mann-Whitney t-test, p = 0.0688; All data are given as means + 
SEM, n.s. = not significant, *P < 0.05, ***P < 0.001. 
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3.2 Emapunil improves MPTP-induced motor impairment  
After evaluation of the protective effect of Emapunil on dopaminergic neuron survival, we 
asked whether Emapunil could also improve the motor performance in MPTP-treated animals. 
To answer this question, we conducted two motor tests. 
3.2.1 Emapunil treatment improves pole test performance 
Firstly, the well-established pole test was used to assess the effects of Emapunil on MPTP 
induced motor-coordination deficits and bradykinesia. When placing mice on the top of a 
vertical pole, we recorded the time they used for turning their bodies downward and for 
climbing down to the ground on day 13 after the first MPTP injection. We found that MPTP + 
DMSO treated mice needed longer time to turn their heads downward than the saline group, 
whereas the MPTP + Emapunil group showed no significant difference compared to saline 
controls (Figure 3.3A) (NaCl group: orientation time = 1.36 ± 0.131 s, n = 15; MPTP + 
DMSO group: orientation time = 1.545 ± 0.1008 s, n = 15; MPTP + Emapunil group: 
orientation time = 1.152 ± 0.066 s, n = 13; one-way ANOVA with Tukey’s post hoc test; in 
between group difference p = 0.04; data are given as means ± SEM). The time to descend 
from the top of the pole to the ground was also recorded, and MPTP + DMSO treated mice 
showed a tendency, although not significant, to spend longer time on the pole compared to the 
control group. MPTP + Emapunil treated mice were faster to reach the ground compared to 
the MPTP + DMSO treated mice and saline controls (Figure 3.3A) (NaCl group: total time = 
5.27 ± 0.24 s, n = 15; MPTP + DMSO group: total time = 5.87 ± 0.281 s, n = 15; MPTP + 
Emapunil group: total time = 4.29 ± 0.273 s, n = 13; one-way ANOVA with Tukey’s post hoc 
test; F(2,40) = 3.366, p = 0.004; data are given as means ± SEM). 
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3.2.2 Emapunil treatment improves the cylinder test performance  
To further assess the effects of Emapunil on motor performance, we performed the cylinder 
test in the subacute MPTP mouse model. The cylinder test measures sensorimotor 
coordination and forelimbs usage during free exploratory activity in mice which are placed in 
a transparent cylinder. It was initially designed to compare motor asymmetry in unilateral 
CNS lesions (Schallert et al. 2000), but can also be used to study forelimb motor coordination, 
by evaluating the percentage of free rears with either no, single, or both forelimbs contact to 
the wall for supporting the body. The cylinder test was previously tested in 6-OHDA (Saal et 
al. 2015) and MPTP (Tönges et al. 2012) mouse models of Parkinsonism. In this test, 5-
minute films were recorded for each mouse when they were freely exploring the cylinder for 
the first time. The total number of rears was divided into 4 patterns: free rears, rears with 
either left or right forelimb, and rears with both forelimbs touching the wall and the 
percentages of each to total rears were calculated.  
Mice with MPTP + DMSO treatment showed the highest frequency of rears supported by 
both forelimbs and the lowest frequency for free rears, which indicated the motor co-
ordination deficiency caused by MPTP. The MPTP + Emapunil treated mice showed a 
significant higher percentage of free rears and lower percentage of rears with both forelimbs 
against the wall, when compared to MPTP + DMSO group (Figure 3.3B) (NaCl group: ratio 
of free rears = 22.9 ± 2.37%, ratio of rears with left forelimb = 4.71 ± 1.27%, ratio of rears 
with right forelimb = 3.48 ± 0.845%, ratio of rears with both forelimbs = 68.9 ± 3.49%, n = 
15; MPTP + DMSO group: ratio of free rears = 13.5 ± 2.82%, ratio of rears with left forelimb 
= 4.07 ± 0.95%, ratio of rears with right forelimb = 5.98 ± 1.37%, ratio of rears with both 
forelimbs = 68.9 ± 3.49%, n = 14; MPTP + Emapunil group: ratio of free rears = 32 ± 2.36%, 
ratio of rears with left forelimb = 6.79 ± 0.01.4%, ratio of rears with right forelimb = 2.92 ± 
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0.99%, ratio of rears with both forelimbs = 58.3 ± 3.66%, n = 13; one-way ANOVA with 
Tukey’s post hoc test; in between group difference: free rears: F(2,39) = 12.91, p = 0.000108; 
rears with both forelimbs support: F(2,39) = 6.494, p = 0.00367; data are given as means ± 
SEM). 
In conclusion, Emapunil treatment significantly improves motor behavior in the subacute 
MPTP mouse model. 
 
Figure 3.3 Emapunil restores motor function  
(A) Histographs show the time used for orienting downward and the total time in the pole test for each 
group. One-way ANOVA with Tukey’s post hoc test; in orienting time p = 0.04, in total time p = 0.0024; 
Data are shown as means + SEM. *p < 0.05, **p < 0.01. (B) Histograph shows the different patterns mice 
used during rearing, either with both forelimbs touching the wall for supporting, with only left or right or 
no forelimb support. One-way ANOVA with Tukey’s post hoc test, in free rears p = 0.000108, in rears 
with both forelimbs support p = 0.00367; data are shown as means + SEM. *p < 0.05, **p < 0.01, ***p < 
0.001.  
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3.3 Emapunil attenuates alterations of dopamine and its 
metabolites induced by MPTP toxicity in vivo 
We next analyzed the effects of Emapunil on the dopamine metabolism at nerve terminals in 
the striatum by quantifying the levels of dopamine and its metabolites using HPLC. 
Dopamine is synthesized from tyrosine and serves as an important neurotransmitter. After re-
uptake into dopaminergic neurons, it is metabolized to 3,4-Dihydroxyphenylacetic acid 
(DOPAC) by monoamine oxidase (MAO), which can be further degraded into homovanilic 
acid (HVA) by COMT in glial cells. Alternatively, dopamine can be directly taken up by glial 
cells and first degraded to 3-methoxytyramine (3-MT) by catechol-O-methyl transferase 
(COMT), and 3-MT can be further degraded to HVA by MAO (Figure 3.4) (Winner et al. 
2017; Meiser et al. 2013). Therefore, DOPAC and HVA are two major metabolites of 
dopamine (Juárez Olguín et al. 2016). 
 
Figure 3.4 Overview of dopamine synthesis and metabolism. 
Figure is adapted from (Winner et al. 2017) 
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To explore the effects of Emapunil in dopamine metabolism, we quantified dopamine, 
DOPAC and HVA in the striatum from five mice per group at day 3 using HPLC. The results 
showed that the striatal dopamine levels in MPTP treated mice were significantly lower 
compared to saline controls, indicating loss of axonal dopamine stores. This reduction was 
significantly attenuated by Emapunil treatment. Furthermore, we assessed the dopamine 
metabolic ratio [(HVA + DOPAC)/dopamine], which is an important indicator for oxidative 
stress. We found that the metabolic ratio was significantly higher in the MPTP + DMSO 
group compared to saline controls, indicative of a predominantly glial dopamine metabolism 
and consistent with dopaminergic nerve terminal loss. In contrast, the MPTP + Emapunil 
treated mice show a significant lower metabolism ratio to a comparable level with saline 
controls (HPLC analysis was done by Éva M. Szegő) (Figure 3.5) (NaCl group: dopamine = 
8.444 ± 0.691 ng/mg, DOPAC = 7.144 ± 0.2925 ng/mg, metabolic ratio = 1.934 ± 0.1684, n = 
5; MPTP + DMSO group: dopamine = 3.293 ± 0.3095 ng/mg, DOPAC = 5.534 ± 0.3939 
ng/mg, metabolic ratio = 3.743 ± 0.3718, n = 5; MPTP + Emapunil group: dopamine = 5.581 
± 0.4028 ng/mg, DOPAC = 6.691 ± 0.4018 ng/mg, metabolic ratio = 2.304 ± 0.1942, n = 5; 
one-way ANOVA with Tukey’s post hoc test; in between group difference: dopamine p < 
0.0001, DOPAC p = 0.02, metabolic ratio p = 0.0008; data are given as means ± SEM). Taken 
together, these data indicate that Emapunil may preserve nigrostriatal innervation by 
protecting dopaminergic terminals.  
 




Figure 3.5 Levels of dopamine and its metabolites analyzed by HPLC  
Levels of dopamine, DOPAC and HVA in the striatum were measured from 5 mice per group at day 3 
using HPLC (A) Dopamine levels; (B) DOPAC levels; (C) Metabolic ratios of (HVA + 
DOPAC)/dopamine. Data are shown as means + SEM; one-way ANOVA with Tukey’s post hoc test; in 
between group difference: p < 0.0001 (dopamine), p = 0.02 (DOPAC), p = 0.0008 (metabolic ratio); n.s. = 
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3.4 Emapunil ameliorates IRE1α/XBP1 pathway activation 
Numerous studies have shown that endoplasmic reticulum (ER) stress is induced upon MPTP 
treatment, which leads to the activation of unfolded protein response (UPR) signaling 
pathways (Kuo et al. 2016). The inositol-requiring enzyme 1 α (IRE1α)/X-box binding 
protein 1 (XBP1) pathway is the most conserved UPR signaling pathway, which was also 
reported to be activated in the subacute MPTP mouse model (Sado et al. 2009a). We assessed 
Xbp1s/XBp1 mRNA ratio in vivo by qPCR from striatum at day 3. MPTP + DMSO treated 
mice showed significantly higher levels of active XBP1s mRNA and XBP1s/Xbp1 mRNA 
ratio compared to saline controls, whereas additional treatment with Emapunil restored XBP1s 
mRNA and XBP1s/Xbp1 mRNA ratio to a comparable level with control group (qPCR was 
done by Éva M. Szegő) (Figure 3.6) (NaCl group were normalized to 1: Xbp1 = 1 ± 0.02093, 
spliced XBP1s = 1 ± 0.045, ratio = 1 ± 0.0473, n = 5; MPTP + DMSO group: Xbp1 = 0.88 ± 
0.067, spliced XBP1s = 1.35 ± 0.0527, ratio = 1.57 ± 0.155, n = 5; MPTP + Emapunil group: 
Xbp1 = 0.904 ± 0.05349, spliced XBP1s = 0.896 ± 0.036, ratio = 1.01 ± 0.0834, n = 5; one-
way ANOVA with Tukey’s post hoc test; in between group difference: Xbp1 p = 0.2532, 
spliced Xbp1s p < 0.0001, ratio Xbp1s/Xbp1 p = 0.003151; data are given as means ± SEM). 
The expression of TSPO is mainly in microglia during inflammation. However, the 
restoration effect of Emapunil on XBP1s activation requires the expression of TSPO in 
neurons, which has never been tested before. As shown in Figure 3.7, we confirmed that 
TSPO is also expressed in dopaminergic neurons by co-staining of mouse substantia nigra 
(SN) brain sections with antibodies against TSPO and TH. 




Figure 3.6 Emapunil treatment mitigates XBP1s mRNA increase 
(A) Unspliced Xbp1 mRNA expression level; (B) spliced XBP1s mRNA expression level; (C) ratio of 
XBP1s/Xbp1 mRNA expression normalized to control group; in between-group difference: Xbp1p = 
0.2532, spliced Xbp1s p < 0.0001, and ratio Xbp1s/Xbp1 p = 0.003151; one-way ANOVA with Tukey’s 





Figure 3.7 Co-immunofluorescence staining against TSPO and TH in SN  
Substantia nigra sections from control mice were co-immunofluorescence stained against TSPO (left, green 
color), and TH (middle, red color). The merged image is shown in the right panel, scale bar = 20 m. 
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3.5 The effects of Emapunil on XBP1s activation depend on 
TSPO 
3.5.1 TSPO expression in LUHMES cells 
To further study the effects of Emapunil on dopaminergic neurons in vitro, we utilized the 
human dopaminergic neuronal cell line LUHMES (Lotharius et al. 2002). First, the 
differentiated post-mitotic LUHMES cells were identified by immunostaining against TH and 
beta-III-tubulin, indicating dopaminergic neurons features (Figure 3.8A). We also confirmed 
the expression of TSPO in LUHMES cells by co-staining with antibodies against TSPO and 
beta-III-tubulin (Figure 3.8B). 
 
Figure 3.8 TSPO is expressed in differentiated LUHMES cells 
(A) LUHMES cells were co-stained against beta-III-tubulin (left, green color) and TH (middle, red 
color); (B) co-immunofluorescence staining against TSPO (left, green color) and beta-III-tubulin 
(middle, red color). Merged image is in the right panel, scale bar = 20 m.  
3.5.2 Emapunil ameliorates MPP+ and rotenone toxicity and ER 
stress in LUHMES cells 
We then quantified cell viability by measuring the released adenylate kinase from cells using 
ToxiLight assay. LUHMES cells were treated with either MPP
+
 or rotenone to induce 
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oxidative stress 12 h after Emapunil treatment at day 7 of differentiation (Krug et al. 2014; 
Giordano et al. 2012). After 24 h incubation, the supernatants were collected for cytoxicity 
measurement. LUHMES cells that were exposed to MPP
+
 or rotenone showed significantly 
increased adenylate kinase compared to DMSO treated control cells, indicating reduced 
viability and survival rate. The MPP
+
 or rotenone toxicity was markedly ameliorated with 
Empaunil treatment, which is in line with our in vivo results (Figure 3.9A) (DMSO group 
were normalized to 1: Fold change (FC) = 1 ± 0.06748, n = 31; DMSO + 5 M Emapunil 
group: FC = 1.216 ± 0.08, n = 31; 10 M MPP
+ 
+ DMSO group: FC = 4.877 ± 0.4397, n = 17; 
10 M MPP
+ 
+ 5 M Emapunil group: FC = 4.024 ± 0.3168, n = 17; 10 M rotenone + 
DMSO group: FC = 5.624 ± 0.2506, n = 14; 10 M rotenone + Emapunil group: FC = 4.042 ± 
0.0871, n = 14; in between group difference F (2, 118) = 9.856, p < 0,0001; two-way 
ANOVA with Holm Sidak post hoc test; data are given as means ± SEM).  
Next, we investigated the ratios of XBP1s/XBP1 mRNA expression levels under rotenone 
induced oxidative stress using qPCR. In accordance with our in vivo results with MPTP 
treated mice, rotenone treatment in LUHMES cells dramatically increased the XBP1s/XBP1 
ratio compared to DMSO controls. In contrast, additional Emapunil treatment significantly 
attenuated the XBP1s/XBP1 ratio, as did the IRE1α/XBP1 inhibitor toyocamycin (Tanabe et 
al. 2018). Toyocamycin treatment showed lower XBP1s/XBP1 ratio compared to the DMSO 
treated controls. Notably, there was no additive effect of combined Emapunil and 
toyocamycin treatment in rotenone exposed cells, which indicates that the protective effect of 
Emapunil is indeed mediated through the IRE1α/XBP1 pathway. In addition, neither 
Emapunil nor toyocamycin treatment alone resulted in XBP1s alterations in LUHMES cell 
culture (Figure 3.9B) (Vehicle group were normalized to 1: XBP1 = 1 ± 0.106, XBP1s = 1 ± 
0.132, ratio = 1 ± 0.041, n = 9; rotenone group: XBP1 = 9.23 ± 3.41, XBP1s = 67.7 ± 22.6, 
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ratio = 8.47 ± 1, n = 9; Toyocamycin group: XBP1 = 0.681 ± 0.181, XBP1s = 0.607 ± 0.171, 
ratio =0.896 ± 0.102, n = 9; Emapunil group: XBP1 = 0.679 ± 0.197, XBP1s = 0.68 ± 0.197, 
ratio = 1.02 ± 0.0424, n = 9; Toyocamycin + Emapunil group: XBP1 = 0.879 ± 0.212, XBP1s 
= 0.823 ± 0.199, ratio = 0.93 ± 0.0884, n = 9; rotenone + toyocamycin group: XBP1 = 0.969 ± 
0.175, XBP1s = 1.23 ± 0.188, ratio = 1.46 ± 0.264, n = 9; rotenone + Emapunil group: XBP1 
= 0.599 ± 0.167, XBP1s = 0.756 ± 0.173, ratio = 1.58 ± 0.252, n = 9; rotenone + toyocamycin 
+ Emapunil group: XBP1 = 1.41 ± 0.404, XBP1s = 2.2 ± 0.724, ratio = 1.48 ± 0.14, n = 9; 
one-way ANOVA with Tukey’s post hoc test; in between group difference XBP1: F (7, 64) = 
5.835, p < 0.0001, XBP1s: F (7, 64) = 8.645, p < 476 0.0001, ratio: F (7, 64) = 45.43, p < 
0.0001; data are given as means ± SEM).  
 
Figure 3.9 Cytoxicity and ER stress were attenuated by Emapunil  
(A) LUHMES cells ToxiLight Cytoxicity assay results. Cells were treated with either MPP
+
 or rotenone, 
with/without additional Emapunil treatment. Control cells were treated with DMSO as solvent control. 
Data are shown as means + SEM, Two-way ANOVA with Holm Sidak post hoc test, p < 0.0001, *p < 
0.05, ***p < 0.001; (B) Ratio of XBP1s/XBP1 in Luhmes cells of different treatment groups. Data are 
shown as means + SEM; one-way ANOVA with Tukey’s post hoc test, in between group difference p < 
0.0001. **p < 0.01, ***p < 0.001. 
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3.5.3 siRNA mediated TSPO down-regulation in LUHMES cells  
To investigate whether the protective effects of Emapunil observed in MPP
+
 and rotenone 
treated LUHMES cells were mediated by TSPO, we performed siRNA mediated TSPO 
downregulation. We first quantified the expression level of TSPO mRNA in LUHMES cells 
by qPCR, which showed a ~ 60% reduction in TSPO siRNA treated cells compared to control 
cells (Figure 3.10A) (TSPO siRNA group: TSPO = 0.417 ± 0.027, n = 9; control siRNA 
group were normalized to 1: TSPO = 1 ± 0.029, n = 9; 2-tailed Welch’s t-test, in between 
group difference p = 0.0048; data are given as means ± SEM). Also, the expression level of 
TSPO protein was reduced to ~ 45% compared to control cells as determined by western blot, 
while TH protein expression was not affected (Figure 3.10B,C,D) (TSPO siRNA group: 
TSPO = 0.445 ± 0.067, TH = 0.897 ± 0.096, n = 3; control siRNA group were normalized to 
1: TSPO = 1 ± 0.071, TH = 1 ± 0.048, n = 3; 2-tailed Welch’s t-test, in between group 
difference p = 0.412; data are given as means ± SEM). 
 
Figure 3.10 siRNA mediated downregulation of TSPO  
  Results 
73 
 
(A) TSPO mRNA quantification in LUHMES cells after TSPO or control siRNA treatment; (B) 
Representative western blot of TSPO, beta-Actin and TH in LUHMES cells treated with either TSPO or 
control siRNA; (C) Quantification of TSPO protein levels normalized to beta-Actin from (B), data are 
shown as means + SEM, 2-tailed Welch’s t-test, p = 0.0048; **p < 0.005; (D) TH protein quantification 
normalized to beta-Actin from (B), data are shown as means + SEM, 2-tailed Welch’s t-test, p = 0.412; n.s. 
= not significant. 
 
3.5.4 Emapunil effects on cell viability and XBP1s activation are 
TSPO dependent  
Next, we investigated whether the protective effects of Emapunil observed in MPP
+
 and 
rotenone treated LUHMES cells were TSPO dependent. We performed ToxiLight assays in 
rotenone treated LUHMES cells either transfected with TSPO or control siRNA. In control 
siRNA transfected cells, Emapunil ameliorated the cytotoxicity induced by rotenone to a 
similar level as in the DMSO treated control. In contrast, the rescue effect of Emapunil was 
compromised in TSPO siRNA transfected cells (Figure 3.11A) (Groups transfected with 
control siRNA: Fold change (FC) in the DMSO group was normalized to 1 = 1 ± 0.026, n = 8; 
FC in the DMSO + 10 M rotenone group = 3.682 ± 0.345, n = 8; FC in the 5 M Emapunil 
+ DMSO group = 1.37 ± 0.114, n = 8; FC in the 5 M Emapunil + 10 M rotenone group = 
1.61 ± 0.152, n = 8; Groups transfected with TSPO siRNA: FC in the DMSO group was 
normalized to 1= 1.165 ± 0.0768, n = 8; FC in the DMSO + 10 M rotenone group = 4.293 ± 
0.357, n = 8; FC in the 5 μM Emapunil + DMSO group = 1.385 ± 0.135, n = 8; FC in the 5 
M Emapunil + 10 M rotenone group = 2.908 ± 0.324, n = 8; in between group difference 
F(3, 55) = 3.365, p = 0.0251; two-way ANOVA with Tukey post hoc test; data are given as 
means ± SEM). Taken together, we confirmed that the protective effects of Emapunil in 
LUHMES cells depend on the presence of TSPO. 
Strikingly, we did not find significant differences between TSPO siRNA and control siRNA 
treated LUHMES cells when exposed to rotenone. We suspected that the toxicity of rotenone 
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may already have reached maximum effects at the 10 M concentration. Therefore, we 
performed rotenone titration experiments as shown in Figure 3.11B. Indeed, the maximum 
toxicity of rotenone was detected at 10 M and did not further increase with higher rotenone 
concentrations (FC in the DMSO group = 1 ± 0.00554, n = 6; FC in the 0.5 M rotenone 
group = 4.18 ± 0.195, n = 6; FC in the 1 M rotenone group = 4.55 ± 0.189, n = 6; FC in the 
2.5 M rotenone group = 6.028 ± 0.229, n = 8;: FC in the 5 M rotenone group = 7.246 ± 
0.104, n = 8: FC in the 10 M rotenone group = 8.559 ± 0.259, n = 8; FC in the 20 M 
rotenone group = 8.518 ± 0.317, n = 8; one-way ANOVA with Tukey post hoc test; in 
between group difference F(6, 42) = 95.5, p < 0.0001; data are given as means ± SEM).  
Next, to further investigate whether ER stress mitigation by Emapunil is also TSPO 
dependent, we quantified XBP1s/XBP1 mRNA ratio by qPCR in rotenone exposed LUHMES 
cells with additional TSPO or control siRNA treatment. We found that with TSPO siRNA 
treatment, the ratios of XBP1s/XBP1 did not significantly differ between the Rotenone + 
Emapunil group and the Rotenone + DMSO group. This further verified that the Emapunil 
effects on mitigating ER stress were mediated by TSPO (Figure 3.12) (Fold Change (FC) in 
the DMSO with control siRNA group = 1 ± 0.029, n = 12; FC in the DMSO with TSPO 
siRNA group = 1.022 ± 0.069, n = 12; FC in the DMSO + 10 M rotenone with control 
siRNA group = 3.66 ± 0.245, n = 12; FC in the DMSO + 10 M rotenone with TSPO siRNA 
group = 3.178 ± 0.204, n = 12; FC in the 5 M Emapunil + DMSO with control siRNA group 
= 0.955 ± 0.03, n = 12; FC in the 5 M Emapunil + DMSO with TSPO group = 1.141 ± 
0.153, n = 12; FC in the 5 M Emapunil + 10 M rotenone with control siRNA group = 1.573 
± 0.14, n = 12; FC in the 5 M Emapunil + 10 M rotenone with TSPO group = 2.515 ± 
0.246, n = 12; in between group difference F(3, 88) = 6.931, p = 0.0003; two-way ANOVA 
with Tukey post hoc test; data are given as means ± SEM). 




Figure 3.11 Emapunil protects from rotenone toxicity in a TSPO dependent manner  
(A) ToxiLight cytoxicity assay in LUHMES cells transfected with either TSPO or control siRNA. Data are 
shown as means + SEM; Two-way ANOVA with Tukey post hoc test, F(3, 55) = 3.365, p = 0.0251; **p < 
0.005; ***p < 0.001; n.s. = not significant; (B) Rotenone toxicity titration in LUHMES cells. Data are 
shown as means + SEM, one-way ANOVA with Tukey post hoc test; in between group difference F(6, 42) 
= 95.5, p < 0.0001; ***p < 0.001; n.s. = not significant. 




Figure 3.12 Emapunil mitigates ER stress mediated by TSPO in LUHMES 
The ratios of XBP1s/XBP1 mRNA expression were quantified by qPCR analysis in LUHMES cells 
treated with TSPO or control siRNA. Data are shown as means + SEM, Two-way ANOVA with Tukey 
post hoc test, F(3, 88) = 6.931, p = 0.0003; n.s. = not significant; **p < 0.005; ***p < 0.001.  
 
 
3.6 Emapunil inhibits microgliosis and astrogliosis in vivo 
In previous studies, neuroprotective effects of TSPO ligands were mediated by anti-
inflammatory modulation of microglia, including EAE mouse model and retinal degeneration 
model (Karlstetter et al. 2014; Scholz et al. 2015; Ravikumar et al. 2016). We thus asked 
whether Emapunil also provided anti-neuroinflammatory effects in the subacute MPTP mouse 
model. To this end, we first quantified striatal microgliosis and astrogliosis by 
immunofluorescence from mice sacrificed at day 15. Three sections containing the striatum 
per brain were stained with antibodies against IBA1 and GFAP, respectively. The number of 
IBA1 positive cells per area in the striatum was significantly increased in mice exposed to 
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MPTP, whereas additional Emapunil treatment showed lower microglia numbers compared to 
the MPTP + DMSO group and did not significantly differ from the NaCl control group. 
Similarly, the number of astrocytes was dramatically increased in the MPTP + DMSO group 
compared to the NaCl controls. However, Emapunil treatment slightly (but significantly) 
attenuated the astrogliosis, which suggests that Emapunil may only have limited impacts on 
astrocytes. Because we did not perform longitudinal analysis, we cannot exclude that 
astrogliosis may need longer recovery time than microgliosis (Figure 3.13) (NaCl group: 
IBA1 positive cells = 180.4 ± 4.125/mm
2
, n = 9; GFAP positive cells = 1.152 ± 0.1288/mm
2
, 
n = 6; MPTP + DMSO group: IBA1 positive cells = 234.7 ± 4.813/mm
2
, n = 10; GFAP 
positive cells = 133.7 ± 4.283/mm
2
, n = 7; MPTP + Emapunil group: IBA1 positive cells = 
190.8 ± 6.627/mm
2
, n = 8; GFAP positive cells = 109.4 ± 3.438/mm
2
, n = 6; one-way 
ANOVA with Tukey’s post hoc test; in between group difference IBA1-positive cells: 
F(2,158) = 33.19, p < 0.0001; GFAP positive cells F(2,111) = 446.5, p < 0.0001; data are 
given as means ± SEM).  





Figure 3.13 Microgliosis and astrogliosis were attenuated by Emapunil  
Representative immunofluorescence images for Iba1
+
 microglia (A) and GFAP
+
 astrocytes (B) from 
striatal tissues at day 15 in DMSO, MPTP and MPTP + Emapunil treated mice. Quantification results of 
IBA1+ microglia (C) and GFAP+ astrocytes (D) from (A) and (B). Data represents total numbers/mm
2
 
and are shown as means + SEM; one-way ANOVA with Tukey’s post hoc test; IBA1-positive cells: 
F(2,158) = 33.19, p < 0.0001; GFAP positive cells F(2,111) = 446.5, p < 0.0001; n.s. = not significant; 
***p < 0.001; Scale bars = 50 μm (A) and 100 μm (B). 
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3.7 Emapunil induces a shift from pro- to anti-inflammatory 
microglia activation state  
Next, we quantified striatal Iba1 and Tspo mRNA expression levels by qPCR from mice 
sacrificed at day 3 (qPCR was done by Éva M. Szegő). We found that Iba1 mRNA level was 
significant higher in the MPTP + DMSO group compared with controls, whereas no 
significant differences were found between the MPTP + DMSO and the MPTP + Emapunil 
group (Figure 3.14A) (The NaCl group was normalized to 1: Iba1 FC = 1 ± 0.1763; MPTP + 
DMSO group: Iba1 FC = 5.633 ± 0.6228; MPTP + Emapunil group: Iba1 FC = 6.842 ± 1.015, 
n =5; one-way ANOVA with Tukey’s post hoc test; in between group difference F(2,12) = 
19.68, p = 0.000163; data are given as means ± SEM). Tspo mRNA level was also increased 
in the MPTP + DMSO group but not in the MPTP + Emapunil or the control group. Because 
TSPO is known to be upregulated in activated microglia, it indicates less inflammatory 
activity in the MPTP + Emapunil group (Figure 3.14B) (The NaCl group was normalized to 1: 
Tspo FC = 1 ± 0.07894, n = 5; MPTP + DMSO group: Tspo FC = 2.342 ± 0.379, n = 5; MPTP 
+ Emapunil group: Tspo FC = 0.7979 ± 0.1375, n = 5; one-way ANOVA with Tukey’s post 
hoc test; in between group difference F(2,12) = 12.52, p = 0.001157; data are given as means 
± SEM). To better understand the microglia activation profiles in different groups, we 
quantified several pro- and anti-inflammatory microglia markers by qPCR using the same 
striatal tissue as for Tspo qPCR. Among the classical M1 microglia activation markers, Cox2 
and Il10 mRNA expression levels were increased in the MPTP + DMSO group compared to 
control group, whereas their expression levels were significantly attenuated in MPTP + 
Emapunil treated animals. Other tested markers, including Tnfa, Il1b and Nos2, also showed 
a trend towards decreased expression levels in the MPTP + Emapunil group compared to the 
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MPTP + DMSO group, whereas the NaCl control group showed the lowest expression levels 
(Figure 3.14C) (NaCl group normalized to 1: TnfaFC = 1 ± 0.3178, Il10 FC = 1 ± 0.1652, 
Il1b FC = 1 ± 0.1329, Mpa2l FC = 1 ± 0.07732, Il6 FC = 1 ± 0.1694, Nos2 FC = 1 ± 0.1704, 
Cox2 FC = 1 ± 0.1734, n = 5; MPTP + DMSO group: Tnfa FC = 5.885 ± 0.6208, Il10 FC = 
11.6 ± 0.5612, Il1b FC = 1.581 ± 0.3056, Mpa2l FC = 1.111 ± 0.07614, Il6 FC = 2.227 ± 
0.3152, Nos2 FC = 2 ± 0.1327, Cox2 FC = 2.746 ± 0.2961, n = 5; MPTP + Emapunil group: 
Tnfa FC = 4.979 ± 0.6865, Il10 FC = 5.365 ± 1.449, Il1b FC = 1.385 ± 0.1907, Mpa2l FC = 
1.158 ± 0.279, Il6 FC = 3.189 ± 0.5172, Nos2 FC = 1.66 ± 0.305, Cox2 FC = 1.539 ± 0.171, n 
= 5; one-way ANOVA with Tukey’s post hoc test; in between group difference Tnfa: F(2,12) 
= 21.75, p = 0.000151; Cxcl10: F(2,12) = 34.86, p = 0.0001; Il1b: F(2,12) = 1.78, p = 0.004; 
Mpa2l: F(2,11) = 0.2, p = 0.8180; Il6: F(2,12) = 9.13, p = 0.0039; Nos2: F(2,12) = 5.55, p = 
0.0197; Cox2: F(2,12) = 16.32, p = 0.00038; data are given as means ± SEM). With regards to 
anti-inflammatory markers, we found that Arg1, Il10, Il4, Mrc1, Ym1 and Fizz2 were 
dramatically increased in the MPTP + Emapunil group, whereas most genes showed no 
alteration or even lower expression levels in MPTP treated mice compared to the NaCl 
control group (Figure 3.14D) (NaCl group normalized to 1: Arg1 FC = 1 ± 0.06473, Il10 FC = 
1 ± 0.04799, Il4 FC = 1 ± 0.08438, Mrc1 FC = 1 ± 0.0555, Ym1 FC = 1 ± 0.1139, Fizz2 FC = 
1 ± 0.2787, n = 5; in the MPTP + DMSO group: Arg1 FC = 0.8055 ± 0.001321, Il10 FC = 
0.9218 ± 0.02449, Il4 FC = 1.905 ± 0.4561, Mrc1 FC = 1.517 ± 0.06856, Ym1 FC = 1.357 ± 
0.225, Fizz2 FC = 1.282 ± 0.2985, n = 5; in the MPTP + Emapunil group: Arg1 FC = 1.259 ± 
0.1289, Il10 FC = 2.478 ± 0.557, IL4 FC = 3.082 ± 0.9407, Mrc1 FC = 1.955 ± 0.1961, Ym1 
FC = 2.21 ± 0.0745, Fizz2 FC = 4.248 ± 0.5753, n = 5; one-way ANOVA with Tukey’s post 
hoc test; in between group difference Arg1: F(2,12) = 6.171, p = 0.016; Il10: F(2,12) = 7.36, p 
= 0.008; Il4: F(2,12) = 2.971, p = 0.089; Mrc1: F(2,12) = 14.84, p = 0.00057; Ym1: F(2,12) = 
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16.75, p = 0.0003; Fizz2: F(2,12) = 19.51, p = 0.00017; data are given as means ± SEM). 
Taken together, Emapunil treatment not only mitigates pro-inflammatory microglia activation, 
but also induces a shift towards anti-inflammatory activation. 
 
Figure 3.14 Emapunil induces microglia from pro- to anti-inflammatory activation 
Relative quantification of mRNA expression levels normalized to the NaCl control group (striatum, day 
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3) (A) pro-inflammatory microglia markers; (B) anti-inflammatory microglia markers; Data are shown 
as means + SEM. One-way ANOVA with Tukey’s post hoc test; in between group difference Tspo: 
F(2,12) = 12.52, p = 0.001157; Tnfa: F(2,12) = 21.75, p = 0.000151; Cxcl10: F(2,12) = 34.86, p = 
0.0001; Il1b: F(2,12) = 1.777, p = 0.004; Mpa2l: F(2,11) = 0.2046, p = 0.8180; Il6: F(2,12) = 9.131, p = 
0.0039; Nos2: F(2,12) = 5.55, p = 0.0197; Cox2: F(2,12) = 16.32, p = 0.00038; Arg1: F(2,12) = 6.171, 
p = 0.016; Il10: F(2,12) = 7.36, p = 0.008; Il4: F(2,12) = 2.971, p = 0.089; Mrc1: F(2,12) = 14.84, p = 
0.00057; Ym1: F(2,12) = 16.75, p = 0.0003; Fizz2: F(2,12) = 19.51, p = 0.00017; *p < 0.05, **p < 0.01, 
***p < 0.001; n.s. = not significant. 
3.8 Whole-transcriptome analysis 
To further investigate the potential pathways mediating the effects of Emapunil, another 
cohort of mice was treated for subsequent transcriptome analysis (done by Eva Benito). Mice 
were dissected at day 3 after treatment, and the striatum was prepared for RNA-seq. Firstly, 
we compared the differentially expressed (DE) genes between the MPTP + DMSO group/the 
MPTP + Emapunil group and the control group (Figure 3.15A). We found 1017 DE genes in 
the MPTP + DMSO group, and 2464 DE genes in the MPTP + Emapunil group. When we 
compared these DE genes between the MPTP + DMSO and the MPTP + Emapunil group, we 
found 834 DE genes were identical, whereas 183 genes were differentially regulated 
exclusively in the MPTP + DMSO group, but not in the Emapunil treatment group. This 
indicates that the differential expression of these 183 genes may be attenuated by Emapunil. 
Interestingly, 1630 genes were differentially expressed in the Emapunil group only. These 
data suggest that Emapunil is not only able to attenuate part of the DE genes induced by 
MPTP, but also has additional effects itself (Figure 3.15B, C).  
Next, the 183 MPTP-specific DE genes were selected for Gene Ontology (GO) functional 
enrichment analysis. Among these genes, the up-regulated MPTP-specific DE ones were 
associated with pathways in innate immune response, ERK and MAPK cascade regulation, 
vesicle-mediated transport, endocytosis, cytokine production, neuron differentiation and 
neurogenesis (Figure 3.15C, D). The down-regulated MPTP-specific DE ones were associated 
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with pathways in cell projection organization and assembly, actin cytoskeleton organization, 
ion transport, lipid and phospholipid metabolic process, cell migration and motility (Figure 
3.15C,D).  
We also analyzed the 1630 Emapunil-specific DE genes using GO functional enrichment and 
network analysis. These genes were linked to a wide range of cellular pathways, including 
positive response to oxidative stress, steroid hormones, regulation of cell and nuclear division, 
positive regulation of endocytosis, negative regulation of inflammatory cytokine production, 
apoptotic signaling pathways, leukocyte-mediated immunity and defense response to bacterial 
origin molecules (Figure 3.16).  
 
Figure 3.15 Whole-transcriptome analysis of MPTP and Emapunil effects 
(A) Heatmap and sample clustering for MPTP + DMSO group or MPTP + Emapunil group DE genes 
compared to NaCl control group; (B) Venn diagram showing the overlaps of DE genes between MPTP + 
DMSO and MPTP + Emapunil group; (C) Heatmap and sample clustering of the 183 MPTP-specific DE 
genes, up-regulated genes in red and down-regulated genes in blue; (D) the most salient GO categories 
from GO functional enrichment analysis of the up-regulated (red, upper panel) and down-regulated (blue, 
lower panel) DE genes from (C). 





Figure 3.16 GO functional enrichment and network analysis of the most salient Emapunil-
specific DE genes 
LFC = log fold change 
 




In this preclinical study, we evaluated the effect of Emapunil and its potential pathways in the 
subacute MPTP mouse model of Parkinsonism as well as in the dopaminergic LUHMES cell 
line. The MPTP mouse model is a widely used toxin-based animal model since it recapitulates 
several features of PD, namely dopaminergic neuron degeneration, neuroinflammation and 
motor deficits.  
Here, 8 weeks old C57BL/6JRj female mice were used, with 5 consecutive days of 30 mg/kg 
MPTP i.p. injection. In addition, 50mg/kg Emapunil were i.p. injected every 48h for 15 days. 
The results indicated neuroprotective effects of Emapunil against dopaminergic neuron loss in 
the substantia nigra, against dopaminergic nerve terminals loss in the striatum, and against 
motor performance impairment. The neuroprotective effect of Emapunil was further 
confirmed in LUHMES cells which were exposed to MPP
+
 and rotenone. 
We also investigated the potential pathways which may explain the neuroprotective effects of 
Emapunil: (i) amelioration of the IRE/XBP1s related UPR pathway; (ii) anti-inflammatory 
activation of microglia. 
4.1  Physiological function of TSPO 
The notion that TSPO was essential and indispensable for cholesterol transport and steroid 
homeostasis emerged in 1997, when a study found embryonic lethality in TSPO global 
knockout mice (Papadopoulos et al. 1997). Subsequent experiments uncovered that the 
function of TSPO was to transport cholesterol from the outer to the inner mitochondrial 
membrane, as the rate-limiting step in steroidogenesis (Rupprecht et al. 2010). However, this 
concept was challenged by the finding that TSPO global knockout mice were viable with 
normal lifespan, behavior, growth, fertility, and also regular cholesterol transport and plasma 
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pregnenolone concentration under healthy condition. However, the TSPO global knockout 
mice in that study showed reduced ATP production when microglia were activated after 
neuronal injury, indicating that TSPO is involved in mitochondrial metabolic activity (Banati 
et al. 2014). Until recently, the functional consequences of TSPO knockout are still under 
debate, as some research groups showed impaired steroid synthesis in TSPO CRISPR/Cas9 
deleted MA-10 Leydig cells (Owen et al. 2017; Barron et al. 2018; Fan et al. 2017), whereas 
others found no significant deficits in the same cells (Tu et al. 2014; Banati et al. 2014; Tu et 
al. 2015; Tu et al. 2016). One of the limitations of this TSPO knockout mouse model is that 
compensatory mechanisms can not be ruled out since the knock out is not inducible at a later 
time point (Papadopoulos et al. 2018). Although the physiological role of TSPO is still 
unclear, all studies indicate that TSPO is a mitochondrial membrane protein which binds to 
cholesterol and can stimulate steroidogenesis under certain circumstances, like reduced 
endogenous steroid levels. This hypothesis is in line with our transcriptome analysis, where 
we found that Emapunil-related DE genes are strongly linked to the neurosteroidsgeniosis and 
hormone-induced steroid production (Figure 3.16).  
4.2 Specificity of Emapunil binding to TSPO  
The selectivity of Emapunil for TSPO binding was previously tested in multiple studies. First, 
binding affinity of Emapunil to nonselective targets were investigated in concentrations up to 
1 M by an in vitro screen, which contained a total of 90 different purified receptors 
(receptors for adenosine, adrenoceptors, bradykinin BK2, dopamine, CCKA, GABA, 
glutamate, histamine, muscarinic, neurokinin, nicotine, opioid, serotonin, sigma, vasopressin 
V1b and hormones), transporter (dopamine, GABA and monoamines) and ion channels 
(calcium, potassium and sodium) (Kita et al. 2004). According to the authors, Emapunil 
  Discussion 
87 
 
showed “no detectable affinity” to any of these targets tested. Another study also showed that 
Emapunil had no direct interaction with rat and human GABAA receptor subunits at the 
cellular level (Rupprecht et al. 2009). Ideally, to test whether Emapunil effects are indeed 
mediated by binding to TSPO, experiments would be repeated in TSPO knockout mice which 
were not possible within the time frame of this project. Therefore, we recapitulated several 
aspects in the dopaminergic LUHMES cell line.  
We detected that the neuroprotective effects of Emapunil against rotenone induced 
cytotoxicity and increased XBP1s/XBP1 mRNA ratio, were significantly attenuated when 
TSPO expression was down-regulated by siRNA (Figure 3.12). Therefore, it is likely that the 
neuroprotective effects of Emapunil we observed in this study are indeed TSPO dependent 
and specific, rather than caused by off-target effects, although this could only be excluded 
using TSPO knockout mice. 
4.3 How are Emapunil’s neuroprotective effects mediated? 
In this study, we detected by qPCR that the spliced XBP1s/XBP1 mRNA ratios were 
significantly increased both in mice and in LUHMES cells when exposed to MPTP (mice), 
MPP
+ 
(cells) or rotenone (cells), and the increased levels were reduced by Emapunil treatment 
(Figure 3.6, Figure 3.12).  
XBP1 is one of the major ER stress response factors and key markers through UPR signaling 
pathways. The active form XBP1s, not only directly activates ER chaperones (Grp78/BiP, 
Grp58, Grp94) and ERAD components to refold and degrade the misfolded proteins, but also 
indirectly mediates lipids, cholesterol and other steroids synthesis (Valdés et al. 2014). 
Most neurodegenerative diseases are characterized by protein misfolding and accumulation, 
ER stress and activated UPR signaling pathways (Dauer and Przedborski 2003). Activated 
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UPR signaling pathway is designed for protein degradation through ERAD pathway and for 
protein translation suppression which would attenuate ER stress (Hetz et al. 2011). 
Conflicting data have been reported regarding effects of increased XBP1s levels. For 
example, in MPP
+
 treated dopaminergic neuron cultures, adenoviral overexpression of XBP1s 
was neuroprotective (Sado et al. 2009b). However, the opposite effects, like apoptotic cell 
death were also reported following chronic activation of XBP1s in multiple diseases, such as 
AD, PD, Prion and Huntington’s disease (Urra et al. 2013; Tabas and Ron 2011; Moreno et al. 
2013).Therefore, a concept named “ER hormesis” was proposed, which concludes that a mild 
XBP1s activation with efficient downstream pathways may provide neuroprotective effects, 
whereas the chronic activation of XBP1s with insufficient downstream pathways could lead to 
apoptosis in diseases (Mercado et al. 2015; Michel et al. 2016). For example, activated 
IRE1/XBP1 pathway exacerbated pathology in the 5xFAD mouse model of Alzheimer’s 
disease (Duran-Aniotz et al. 2017b). In the 6-OHDA rat model of parkinsonism, treatment 
with β-asarone, an IRE1/XBP1 pathway inhibitor, was neuroprotective (Ning et al. 2016). In 
accordance with previous reports, our findings from in vivo and in vitro experiments show 
that the neuroprotective effects of Emapunil in MPTP treated mice is associated with 
attenuated activation of the IRE1/XBP1 signaling pathway, which is also paralleled by lower 
neurotoxicity in LUHMES cells.  
4.4 Emapunil shifts activated microglia from M1 to M2 
XBP1s activation is tightly connected to ROS-mediated oxidative stress and inflammatory 
response in many neurodegenerative diseases. It was shown that activation of the IRE-
1α/XBP1s pathway itself stimulates the release of several pro-inflammatory cytokines, like 
TNF-α, IL-6, and IL-1β (Wang et al. 2015c; Chandra et al. 2017). Previously, several TSPO 
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ligands have already been demonstrated to improve neuron survival and attenuate 
neuroinflammation in different neurodegenerative and neuroinflammatory diseases, such as 
Alzheimer’s disease (Barron et al. 2013), acute retina degeneration (Scholz et al. 2015), 
traumatic brain injury (Papadopoulos and Lecanu 2009) and depression (Gavioli et al. 2003).  
Historically, activated microglia were divided into pro-inflammatory M1 state and anti-
inflammatory M2 state, which contained M2a (associated with tissue repair and 
phagocytosis), M2b (a selective up-regulation of phagocytosis as well as modulation of 
inflammatory response) and M2c (associated with tissue regeneration, extracellular matrix 
repairing and de-activation of M1/Th1 immune responses) sub-phenotypes. Although the 
M1/M2 classification of activated microglia was thought to be over-simplistic and has already 
been replaced by the new concept proposing that multiple and mixed phenotypes exist in 
single microglia, they are still useful to evaluate the general states of activated microglia in 
the disease. The pro-inflammatory M1 activated microglia and its effects have been 
implicated in the pathogenesis of PD as well as in PD animal models (Hirsch and Hunot 2009; 
Gao et al. 2008; Wang et al. 2015c).  
Following MPTP treatment, we found that several M1 marker mRNA expression levels were 
upregulated, like Tnf-α, Cxcl10, Nos2, and Cox2, which is in accordance with a previous 
report in the subacute MPTP treated mice (Calvello et al. 2017). In contrast, Emapunil 
treatment significantly attenuated Il10 and Cox2 expression. Non-significant reductions were 
found for Nos2 and Tnf-α (Figure 3.14). In parallel, several M2 microglia markers were 
significantly upregulated with Emapunil treatment, like Arg1 (M2a), Il10, Il4 (with only a 
trend, no significance), Mrc1, Ym1 and Fizz2 (M2a) (Figure 3.14). As reported previously, 
Il10 can stimulate M2c activation, which in turn suppresses M1-associated pro-inflammatory 
activity (Franco and Fernandez-Suarez 2015; Michell-Robinson et al. 2015). Thus we 
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concluded that Emapunil treatment induced a shift of the activated microglia from pro- to 
anti-inflammatory state.  
4.5 Emapunil has additional functional pathways apart from 
counteracting MPTP toxicity 
Analyzing the transcriptome profiles in neurodegenerative diseases is a useful tool for 
systematically identifying potential mechanisms and pathways. GO functional network 
analysis of the 1017 genes which were affected by MPTP treatment, revealed that the most 
salient genes are involved in mitochondrial membrane function, metal transport, calcium 
signaling, inflammatory response and intracellular transport (Figure 3.15), which is in line 
with previous transcriptome sequences in MPTP mouse model of PD (Cheng et al. 2016; 
Klemann et al. 2016). Strikingly, there are only 183 MPTP-specific DE genes which are 
reinstated by Emapunil treatment. These genes are mostly linked to innate immune response 
and cytokine production pathways, which is in accordance with previous reports and our 
findings that Emapunil could alter microglia activation state (Figure 3.15) (Rashid et al. 
2018a; Rashid et al. 2018b; Scholz et al. 2015).  
However, the majority of Emapunil-associated DE genes are not MPTP related. Network 
analysis of these Emapunil-specific genes included networks also linked to the regulation of 
cytokine production and other immune-related pathways. Additionally, they are linked to the 
positive response to oxidative stress and steroid homeostasis (Figure 3.16).  
4.6 Sex differences in animal models  
As previously reported, the expression levels of TSPO between sexes are different, for 
instance, male mice and men with myocarditis show significant higher TSPO expression 
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levels compared to female, which are due to testosterone (Fairweather et al. 2014). Male 
Drosophila also exhibit higher TSPO mRNA than females (Lin et al. 2015). Also, TSPO is 
crucial for steroidogenesis and hormone-induced steroid formation in adrenal and testis as 
reported in the steroidogenic cell-specific TSPO knockout mice (Fan et al. 2015), 
Furthermore, it was already reported that several TSPO ligands could upregulate the gonadal 
testosterone production (Chung et al. 2013; Le et al. 2014). Therefore, it is plausible to 
speculate that TSPO effects may be different between genders, so we only studied the 
Emapunil effects in female mice, and the transcriptome results in this study also indicate that 
the Emapunil is involved in the hormone-related steroid production pathways, which further 
support the hypothesis that Emapunil effects may differ in male versus female mice.  
4.7 Summary of the mechanisms for the protective effects of 
Emapunil 
Several TSPO ligands showed neurosteriodogenesis enhancement, for example, etifoxine 
treatment correlated with increased concentrations of pregnenolone, progesterone, and 
allopregnanolone in brain and plasma of male control rat (Verleye et al. 2005). Treatment 
with another TSPO agonist, FGIN-1-27, has also able to increase the brain pregnenolone 
concentration in the adrenalectomized rat (Romeo et al. 1993). Previously, Emapunil was 
proposed to exert anxiolytic effects as a TSPO agonistic ligand (Kita et al. 2004), and its 
treatment significantly attenuated anxiety symptoms in an induced panic disorder rat model 
and neuropeptide fragment CCK4 challenged male volunteers (Rupprecht et al. 2009). Both 
studies have shown that Emapunil induced neurosteriodogenesis (Rupprecht et al. 2009). 
Furthermore, several recent studies also showed increased neurosteroids production after 
Emapunil treatment both in vivo and in vitro models (Wolf et al. 2015; Ravikumar et al. 
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2016). Therefore, it is likely that Emapunil acts partially by modulating neurosteriodogenesis 
(Costa et al. 2016). 
Importantly, neurosteroids can regulate genes expression by modulating GABAA, NMDA and 
also various other cells surface receptors. However, many different patterns of neurosteroids 
regulation by different TSPO ligands have been reported across studies, the various readouts 
of these studies seem to be dependent on the experimental parameters, ligand treatment 
durations, and brain regions of interest (Giatti et al. 2009; Barron et al. 2013). Because we 
have not quantified neurosteroids and their concentrations in the brain during this study, the 
precise effects of Emapunil on neurosteroidogenisis are still unclear and need further 
investigation. We conclude that the neuroprotective effects of Emapunil may at least partially 
be mediated by modulation of neurosteroidogenesis. 
4.8 The possibility to use Emapunil as a potential drug in PD 
Emapunil is orally available and able to cross the blood-brain barrier (Owen et al. 2012; 
Rupprecht et al. 2009). Also, Emapunil (90 mg/day) was already tested to be safe and 
tolerable in a clinical trial with healthy volunteers who were challenged with a 
pharmacological panic disorder paradigm. The reported side effects of Emapunil were 
comparable with those of the placebo group (Rupprecht et al. 2009). Novartis then launched a 
clinical phase II trial in patients with generalized anxiety disorder (ClinicalTrials.gov 
identifier: NCT00108836). This trial was discontinued due to lack of therapeutic efficacy. 
This may have, at least partially, been caused by polymorphism (A147T) in TSPO which was 
not controlled for (Owen et al. 2011; Selvaraj and Tu 2016). Homozygous A147T carriers 
have a much lower binding affinity of TSPO to most of its synthetic ligands (Owen et al. 
2012) compared to controls. To overcome this problem, all TSPO ligands have been tested for 
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sensitivity to this single nucleotide polymorphism (SNP), and the SNP carriers can be 
genetically identified using blood leukocytes. A147T carriers could then be treated with 
higher doses to compensate for lower binding affinity (Alam et al. 2017). Taken together, we 
propose that Emapunil may be an interesting new approach for clinical application in PD 
treatment.  
4.9 Limitations of this study 
We have shown protective effects of Emapunil in the MPTP mouse model of Parkinsonism, 
and MPP
+
/Rotenone treated LUHMES cells. However, this study also has several limitations. 
First, we have only tested Emapunil effects in MPTP treated female mice. Male mice should 
also be tested in future studies, which should contain male gonadectomized mice and non-
gonadectomized mice. 
Secondly, the dose of Emapunil (50 mg/kg body weight) used for in vivo study was relatively 
high, although it was comparable with the concentrations used in previous studies in mice. 
Ideally, the doses of Emapunil should include multiple concentrations in future studies, from 
low to high, to comprehensively compare its effects.  
Also, since we have not repeated the experiments in TSPO knockout mice, it is impossible to 
rule out potential off-target effects of Emapunil, which should be studied in future. 
Additionally, the neurosteroidogenesis effects of TSPO ligands (including Emapunil) are 
under intensive research in multiple models, and conflicting results were presented in the last 
years. Although we provided indirect evidence that Emapunil is involved in steroid 
production by transcriptome analysis, it would be informative to quantify the neurosteroids 
concentrations in brain or plasma in future Emapunil studies. 
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5 Conclusions  
PD is a devastating neurodegenerative movement disorder. Although symptomatic treatment 
by the dopamine precursor L-DOPA or dopamine agonists can temporarily improve motor 
symptoms, no disease-modifying therapy exists yet. 
In this study, we used in vivo (MPTP) and in vitro (MPP
+ 
and Rotenone) models to investigate 
the effects of Emapunil (= AC-5216 or XBD-173), a synthetic TSPO ligand. With 
administration of Emapunil in female MPTP exposed mice and MPP
+
 treated LUHMES cells, 
we quantified: (i) the dopaminergic neurons and total neurons in SNpc by stereology; (ii) the 
striatal dopamine turnover by HPLC; (iii) the motor performance by pole and cylinder tests; 
(iv) LUHMES viability by Toxilight assay. We found that Emapunil treatment ameliorates 
dopaminergic neuron degeneration, preserves striatal dopamine metabolism and attenuates 
motor deficits.  
We further identified potentially protective downstream pathways of Emapunil: (i) we 
confirmed by qPCR and IF that Emapunil could mitigate ER stress by inhibiting IREα/XBP1 
related UPR in vivo and in vitro. (ii) we unveiled by qPCR analysis that activated microglia 
were shifted from pro- to anti-inflammatory state (iii) we also found that Emapunil mitigated 
MPTP-associated differentially expressed genes by whole transcriptome assay. Interestingly, 
Emapunil also exhibits other potential effects by altering expression levels of genes which are 
unaffected by MPTP. These altered genes are related to oxidative stress and negative 
regulation of inflammatory cytokine production, leukocyte-mediated immunity and defense 
response to bacterial origin molecules. 
Given that Emapunil crosses the BBB and has already been tested to be safe and orally 
available, it may be an interesting new approach for further clinical studies in PD. 
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